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ABSTRACT 
 
 
 MCL-1, a well-known pro-survival BCL-2 family member, is indispensable for 
the survival of various cellular lineages and is also among the most frequently amplified 
genes in a variety of human malignancies. Gene ablation studies previously revealed that 
Mcl-1 deficiency leads to embryonic lethality around E3.5 during peri-implantation stage. 
Strikingly, the study did not detect any increase in apoptotic cells of the blastocyst, 
indicating a function of MCL-1 beyond regulating apoptosis. Our previous studies 
revealed an unrecognized role of MCL-1 in promoting mitochondrial physiology, which 
is independent of its classical anti-apoptotic function and requires being imported into the 
mitochondrial matrix. In order to understand the role of MCL-1 in early embryonic 
development, we used CRISPR-Cas9 to target Mcl-1’s start codon on established 
embryonic stem cells (ESCs). This approach resulted in the establishment of ESCs in 
which MCL-1’s N-terminus was truncated. Biochemical evaluation revealed that N-
terminal-deleted MCL-1 retains anti-apoptotic function. However, this truncated MCL-1 
is restricted to the mitochondrial outer membrane and functionally these mutated ESCs 
showed a dramatic defect in differentiation into the three embryonic germ layers-
ectoderm, mesoderm, and ectoderm. These data suggest that in addition to MCL-1’s 
required antagonism of cell death by the C-terminal region, MCL-1’s N-terminus is 
required for efficient cellular differentiation, potentially by facilitating MCL-1’s import 
into the mitochondrial matrix. 
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CHAPTER 1.    INTRODUCTION 
 
 
The BCL-2 Family and Apoptosis 
 
 Apoptosis, or programmed cell death, is important for the proper development 
and maintenance of homeostasis throughout the life of all mammals. Dysregulation of 
this genetic program leads to human diseases including cancers, autoimmune diseases, 
and neurodegenerative disorders [1]. Apoptosis is initiated by cell death stimuli and 
converges on the activation of caspases, and cysteinyl aspartate proteases which cleave 
protein substrates within the doomed cells to trigger the apoptotic process [2]. Two death 
pathways can be distinguished by whether BCL-2 family is required and which caspases 
are involved [3] (Figure 1-1). 
 
 The extrinsic or death-receptor pathway is triggered by the aggregation of death 
receptors (members of the tumor necrosis factor (TNF) receptor family, such as Fas or 
TNF receptor-1 (TNFR1)) upon extracellular ligand stimulation. The death receptors 
recruit and activate the initiator caspase-8, causing subsequent recruitment of 
downstream caspase-3, -6, or -7, without requirement of the BCL-2 family. In certain cell 
types, most notably hepatocytes, the extrinsic pathway can intersect the intrinsic pathway 
through capsase-8 cleavage-mediated activation by pro-apoptotic BH3-only protein BID 
[2] (Figure 1-1). 
 
 On the other hand, the intrinsic pathway, or mitochondrial pathway, is strictly 
regulated by the BCL-2 family members [3]. The BCL-2 family is composed of anti-
apoptotic and pro-apoptotic members that share homology with four conserved 
amphipathic alpha helical segments named BCL-2 homology domains (BH) numbered 
BH1-4 [2]. Anti-apoptotic members (such as BCL-2, BCL-XL, MCL-1, A1 and BCL-w) 
possess all four BH domains and form a hydrophobic pocket capable of binding the BH3 
domains of other pro-apoptotic members to antagonize apoptosis. The pro-apoptotic 
members can be further subdivided according to the number of BH domains they possess; 
multidomain pro-apoptotic members (BAX, BAK and BOK) and the divergent subset of 
BH3-only members (BAD, BIK, BID, BIM, NOXA, PUMA, etc.) [4-6] (Figure 1-2). 
The central dogma for the BCL-2 family in apoptosis is that death signals trigger the 
activation of BH3-only proteins which can promote the oligomerization of BAX and 
BAK. BAX and BAK oligomers permeabilize the outer mitochondrial membrane (OMM) 
and induce the release of several apoptogenic proteins including cytochrome c. Once 
cytochrome c is released, it binds to the cytosolic protein apoptotic protease-activating 
factor-1 (APAF-1) to facilitate the formation of apoptosome which can recruit and 
activate pro-caspase-9. Activated initiator caspase-9 further activates effector caspases 
and triggers a cascade of events leading to apoptosis [7] (Figure 1-1). 
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Figure 1-1. Scheme depicting intrinsic and extrinsic arms of apoptosis 
Apoptosis can be induced by cell surface receptors, such as FAS and tumor necrosis 
factor receptor-1 (TNFR1) (extrinsic pathway, right), or by various genotoxic agents, 
metabolic insults or transcriptional cues (intrinsic pathway, left). The intrinsic pathway 
starts with BH3-only protein induction or post-translational activation, which results in 
the inactivation of some BCL-2 family members. This relieves inhibition of BAX and 
BAK, which in turn promotes apoptosis. Some BH3-only proteins, such as BIM and 
PUMA, may also be able to activate BAX and/or BAK (as shown by the dotted line). 
Once activated, BAX and BAK promote cytochrome c release and mitochondrial fission, 
which leads to the activation of APAF-1 into an apoptosome and activates caspase-9 to 
activate caspase-3. Caspases in turn cleave a series of substrates, activate DNAses and 
orchestrate the demolition of the cell. The extrinsic pathway can bypass the 
mitochondrial step and activate caspase-8 directly, which leads to caspase-3 activation 
and cell demolition. The BCL-2 family regulates the intrinsic pathway and can modulate 
the extrinsic pathway when cleavage of BID communicates between the two pathways. 
Reprinted with permission from Macmillan Publishers Ltd: Youle RJ, Strasser A. 2008. 
The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell 
Biol 9: 47-59. 
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Figure 1-2. The BCL-2 family 
The BCL-2 family comprises pro-apoptotic and anti-apoptotic members that share 
homology with four conserved amphipathic alpha helical segments named BH1-BH4. 
The highly conserved anti-apoptotic family members (BCL-2, BCL-XL, MCL-1 and A1) 
contain all four BH domains, of which the BH1-BH3 domains structurally form a pocket 
capable of binding the BH3 domains of other family members. Unlike the anti-apoptotic 
members, pro-apoptotic members can be subdivided by the number of BH domains they 
possess. The more conserved multidomain pro-apoptotic members (BAX, BAK, and 
BOK) possess the BH1, BH2 and BH3 domains, which have been also shown to form a 
pocket by NMR structural analysis. In contrast, the BH3-only members (BID, BAD, 
BIM, BIK, NOXA and PUMA) contain only the BH3 minimal death domain and do not 
show sequence conservation outside this domain. Reprinted with permission from 
Macmillan Publishers Ltd: Opferman JT, Korsmeyer SJ. 2003. Apoptosis in the 
development and maintenance of the immune system. Nature Immunology 4: 410-415. 
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Myeloid Cell Leukemia-1 
 
 
Anti-apoptotic MCL-1 and Cell Survival 
 
 MCL-1 is a pro-survival BCL-2 family member that was previously cloned as an 
early response gene up-regulated during TPA-induced differentiation of ML-1 human 
myeloid leukemia cell line [8]. Sequence comparison of mammalian anti-apoptotic BCL-
2 family revealed that C-terminus of MCL-1 shares significant homology with BCL-2 
and BCL-XL and contains three BH domains (BH2, BH1 and BH3) that form a 
hydrophobic cleft to which a BH3 amphipathic alpha-helix of other pro-apoptotic 
members can bind [9]. However, MCL-1’s N-terminus is mostly unstructured and 
contains signal sequence like characteristics, like PEST sequences (enriched in proline, 
glutamic acid, serine, and threonine), accompanied by four pairs of arginines [8]. These 
prominent features are also present in various oncoproteins and other proteins which 
undergo rapid turnover [8]. Significantly, studies showed that BH domains were not 
disrupted by a 151 N-terminal or 23 C-terminal amino acids truncation because the 
truncated mutant retains the ability to interact with BIM [10]. Therefore, neither the N-
terminus nor C-terminus of MCL-1 is required for its anti-apoptotic function.  
 
 MCL-1’s non-redundant and distinct role, compared with other pro-survival BCL-
2 family members, has been uncovered by gene-ablation methods. Bcl-2 knockout mice 
were viable at birth but displayed growth retardation and early postnatal mortality with 
severe lymphoid apoptosis, polycystic kidneys, and hypopigmentated hair [11]. Bcl-XL 
deficient mice died around embryonic day (E) 13 with dramatic apoptosis of immature 
hematopoietic cells and neurons [12]. Bcl-w and A1 knockout mice have also been proved 
viable but manifested as spermatogenesis defects and minor defects in hematopoiesis, 
respectively [13-15]. Significantly, deletion of Mcl-1 resulted in embryonic lethality due 
to peri-implantation failure around E3.5 [16].  
 
 Induced deletion of Mcl-1 during early stage of lymphocyte differentiation leads 
to dramatically increased apoptosis and arrested the lymphocyte development at pre-B-
cell and double-negative T-cell stages. Similar studies also showed MCL-1 is required for 
the survival of T cells at multiple stages [17, 18]. In addition, Mcl-1-induced deletion in 
early hematopoietic cells results in severe anemia and profoundly reduced bone marrow 
cells including hematopoietic stem cells (HSCs), common myeloid progenitors (CMPs), 
and common lymphoid progenitors (CLPs) [19] (Figure 1-3). MCL-1 also plays a 
selective role during myelopoiesis, supported by the observation that lineage-specific 
deletion of Mcl-1 in myeloid precursors resulted in loss of mature neutrophils, but not 
macrophages or monocytes [20]. However, although MCL-1 is dispensable for the 
survival and differentiation of mature macrophages, it plays a necessary role in regulating 
macrophage effector responses during bacterial phagocytosis [21]. Moreover, studies also 
identified the absolute requirement for MCL-1 in the sustained survival of NK cells in 
vivo under the direct regulation of IL-15 and the survival as well as maintenance of 
plasma cells [22, 23]. In contrast, loss of BCL-2 and BCL-XL leads to defects of mature  
 5 
 
 
Figure 1-3. Role of anti-apoptotic regulators during hematopoiesis 
All blood cell lineages arise from a hematopoietic stem cell (HSC) that is capable of self-
renewal and has an indefinite lifespan. HSCs give rise to multipotent progenitors (MPPs) 
that retain the ability to give rise to all blood cell lineages, but lack long-term self-
renewal capacity. MPPs can produce two progenitors, common myeloid progenitors 
(CMPs) and common lymphoid progenitors (CLPs). CLPs can produce the lymphoid 
lineages (B, T, and perhaps NK cells). CMPs produce at least two other oligopotent 
progenitor populations, the megakaryocyte erythroid progenitor (MEP) that produce red 
blood cells (erythrocytes) and megakaryocytes (generate platelets) and the granulocyte 
monocyte progenitor (GMP) that produces granulocytes (neutrophils) and monocytes 
(macrophages). Listed beside each differentiation step or progenitor population are the 
known anti-apoptotic regulators that promote the survival of the given population. Anti-
apoptotic MCL-1 has multiple checkpoints, because it has been illustrated to be critical 
for the survival of several multipotent and oligopotent progenitor populations (HSC, 
CMP, CLP, and GMP) and for the differentiation of granulocytes, but interestingly not 
the monocyte lineage. A1-a, a murine ortholog of BFL-1, and other A1 isoforms have 
also been shown to play an important role in promoting neutrophil survival in response to 
stress but are not absolutely required for development, primarily effecting mature cell 
survival (indicated by open arrowhead). A1 isoforms also play a role, but are not essential 
in lymphoid development. In the erythroid lineage, it appears that anti-apoptotic BCL-XL 
is the essential survival molecule, but unpublished data indicate that MCL-1 may also 
play an essential role during early differentiation. In the megakaryocytic lineage, it 
appears that, although neither MCL-1 nor BCL-XL is solely responsible for survival, the 
two pro-survival molecules appear to have overlapping functions (indicated by open 
arrowheads) in promoting megakaryocyte survival. Reprinted with permission from 
Elsevier Ltd: Perciavalle RM, Opferman JT. 2013. Delving deeper: MCL-1’s 
contributions to normal and cancer biology. Trends in Cell Biology 23: 22-29.  
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lymphocytes and red blood cells, respectively [11, 24]. A1 isoforms play a role, but are 
not indispensable in granulocyte and lymphoid development [14, 25]. These studies 
indicate MCL-1 is essential for the survival and differentiation of multiple hematopoietic 
lineages while the other pro-survival members play much more selective roles in 
hematopoiesis (Figure 1-3).  
 
 In addition to its essential role at different stages of hematopoiesis, MCL-1 is an 
important pro-survival factor in the hearts supported by the evidences that cardiac-
specific ablation of Mcl-1 resulted in a rapidly fatal, dilated cardiomyopathy by a loss of 
cardiac contractility, abnormal mitochondria ultrastructure, and defective mitochondrial 
respiration [26, 27]. MCL-1 is also a required molecule for cortical neurogenesis and the 
survival of neurons under DNA damage. Induced deletion of Mcl-1 resulted in 
widespread cell death of neuronal progenitors and predisposed neurons to acute DNA 
damage [28]. Moreover, MCL-1 has been reported to be expressed in many normal 
human tissues, such as various epithelial tissues, neuroendocrine cells, sympathetic 
neurons, pancreatic islets cells, Leydig cells of the testis, cardiac muscles, skeletal 
muscles, chondrocytes, and hepatocytes [29, 30]. The function of MCL-1 in many of 
those human tissues still remains to be established.  
 
 MCL-1 is also one of the most frequently amplified genes in a variety of human 
cancers, such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia 
(AML), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), 
neuroblastoma, melanoma, breast, lung cancer, etc. [31]. More importantly, elevated 
level of MCL-1 expression often correlates with disease progression, chemotherapeutic 
resistance and relapse [32-35]. The rationale for cancer cells displaying high level of 
MCL-1 is that they often violate important cellular checkpoints which can drive the cells 
to die through apoptosis. Thus, cancer cells need certain strategies for survival under the 
apoptotic stress by either downregulating pro-apoptotic regulators or, more frequently, 
upregulating pro-survival members like MCL-1 [36]. Kotschy et al. developed a small 
molecule S63845 that specifically binds to the BH3-binding groove of MCL-1 with high 
affinity and showed its potent anti-tumor activity with an acceptable safety margin either 
alone or in combination with other anti-cancer drugs in treating a wide range of tumors, 
including multiple myeloma, leukemia, lymphoma cells and various solid tumors [37].  
 
 
Non-canonical Function of MCL-1 
 
 
 Sub-mitochondrial Localization of MCL-1.  MCL-1 protein usually appears as 
a doublet (40 kD and 36 kD) or even triplet (40 kD, 38 kD and 36 kD) on immunoblots of 
many cell types. Several approaches have been adopted to decipher the banding pattern 
[38]. Phosphorylation of MCL-1 has been proposed to give rise to the 40 kD isoform, 
however, phosphatase treatment does not abolish the 40 kD species. It has been suggested 
that non-canonical translational initiation produces the faster-migrating 36 kD protein, 
however, mutation of the start codon of MCL-1 only generates a 30 kD truncated protein 
from a downstream ATG codon. Furthermore, ablation of the putative splice donor and 
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acceptor still gives rise to the same banding pattern indicating that a non-canonical 
messenger RNA splicing is not the reason [38]. Therefore, proteolytic cleavage is the 
most likely contributor to the pattern. Indeed, Edman sequencing reveals two cleavage 
sites, one between isoleucine 10 and glycine 11 and another between leucine 33 and 
valine 34. Consequently, proteolytic cleavage of the N terminus of MCL-1 generates 
three different MCL-1 species: full-length 40 kD, middle band 38 kD cleaved at 
isoleucine 10 and lower band 36 kD cleaved at leucine 33 [38]. 
 
 Unexpectedly, further experiments exhibited different mitochondrial sub-
localization; the upper and middle forms of MCL-1 (40 kD and 38 kD) reside in the outer 
mitochondrial membrane (OMM) as both species are sensitive to proteinase K digestion 
performed on the isolated mitochondria, whereas the lower form (36 kD) appears to be 
confined within the mitochondrial matrix as it is completely resistant to enzyme 
digestion. Moreover, the importation of MCL-1 into the mitochondria is mediated by the 
translocases of outer membrane (TOM) and inner membrane (TIM) supported by the 
evidence that RNA-mediated interference (RNAi) gene silencing of either TOM40 or 
TIM50 abrogates its import, rendering it completely proteinase K sensitive [38]. A 
similar study also showed that the fast-mobility (FM) isoform of MCL-1 is localized to 
the mitochondrial matrix and that a mitochondrial processing peptidase (MPP) is 
responsible for the N-terminal processing of MCL-1 to generate the FM species. The N-
terminal 33 amino acids of mouse MCL-1 serve both as mitochondrial targeting and 
processing signal [39].  
 
 
 MCL-1 Possesses Multiple Functions in Mitochondria.  Perciavalle et al. 
further have successfully made mutants to dissect MCL-1’s two isoforms and shown that 
two species of MCL-1 retain different functions due to distinct subcellular localization. 
The OMM localized MCL-1 performs the classical anti-apoptotic function by 
antagonizing BAX and BAK. However, the matrix localized MCL-1 does not possess 
anti-apoptotic activity, but plays a role in maintaining mitochondrial ultrastructure, 
promoting mitochondrial fusion and fission, supporting the assembly of ATP synthase 
oligomers and oxidative phosphorylation. As supported by the SV40-transformed Mcl-
1flox/flox Rosa-ERCreT2 MEFs, when deletion of Mcl-1 is induced by tamoxifen, it results 
in abnormal mitochondrial cristae structure, delayed mitochondrial fusion and fission, 
decreased ATP levels, mitochondrial membrane potential, oxygen consumption rates 
(OCRs), mitochondrial DNA contents, increased reactive oxygen species (ROS), and 
defected electron transport chain (ETC) supercomplexes and ATP synthase 
oligomerization.  These phenotypes could be only rescued by full-length or matrix 
localized species of MCL-1 but not by the OMM localized isoform [38]. Therefore, other 
than its classical anti-apoptotic function, MCL-1 performs multiple functions in 
mitochondria in promoting mitochondrial physiology and supporting mitochondrial 
ultrastructure [40] (Figure 1-4). However, whether MCL-1 functions directly or 
indirectly to facilitate mitochondrial physiology still requires further investigation.  
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Figure 1-4. Model for MCL-1’s potential functions in mitochondria 
MCL-1 possesses multiple functions in mitochondria. (a) On the outer mitochondrial 
membrane (OMM), MCL-1 functions like other anti-apoptotic BCL-2 family members 
where it acts to prevent the activation of BAX and BAK to prevent cell death. MCL-1 
can directly bind BH3-only family members, such as BIM, sequestering them away from 
the pro-apoptotic effectors BAX and BAK. Alternatively, MCL-1 may directly bind BAX 
and BAK and maintain them in an inactive conformation. (b) During mitochondrial 
importation, the full-length MCL-1 is proteolytically truncated at its amino terminus. The 
truncated, matrix-localized MCL-1 resides within the inner mitochondrial membrane 
(IMM), where it functions to maintain mitochondrial cristae ultrastructure and promotes 
the assembly of the electron transport chain (ETC) complexes into higher-order 
assemblies known as supercomplexes. The assembly into supercomplexes has been 
shown to facilitate electron transport efficiency and reduce the production of deleterious 
reactive oxygen species. Additionally, matrix-localized MCL-1 facilitates the higher 
order assembly of the ATP synthase complexes into dimers and oligomers. Proper 
assembly of oligomeric ATP synthase has been implicated as being an important 
determinant of inner membrane cristae structure. Genetic ablation of Mcl-1 results in 
defects in both supercompexes and ATP synthase oligomer assembly. Whether MCL-1 
acts directly or indirectly to facilitate these macromolecular assemblies of the electron 
transport supercomplexes or ATP synthase oligomers remains unclear. Reprinted with 
permission from Elsevier Ltd: Perciavalle RM, Opferman JT. 2013. Delving deeper: 
MCL-1’s contributions to normal and cancer biology. Trends in cell biology 23: 22-29. 
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Mitochondria in Human Development and Diseases 
 
 Mitochondria are cytosolic double-membrane bound organelles found in almost 
all eukaryotic organisms and are known to be essential for cellular life and death 
regulation. They play a critical role in the life of the cell by carrying out energy-yielding 
oxidative reactions and electron transport chain activities which provide vast majority of 
ATP necessary for all cellular functions. Interruption of this mitochondrial function in 
vivo results in death, as dramatically presented by the mitochondrial electron transport 
chain (ETC) poisons as cyanide [41]. The proteins involved in oxidative phosphorylation 
(OXPHOS) and ETC components reside within the mitochondrial inner membrane. The 
ETC utilizes hydrogens generated through either the tricarboxylic acid (TCA) cycle from 
carbohydrates or the fatty acid β-oxidation from fats and atomic oxygen to make ATP 
and water [42, 43] (Figure 1-5). Moreover, OXPHOS also generates the major 
endogenous source of reactive oxygen species (ROS) as byproducts. Mitochondrial ROS 
are essential signaling pathway molecules as well as potent mitogens, however, too much 
ROS is toxic to the cells and can result in cellular death. Mitochondrial ROS production 
and redox balance are modulated by the mitochondrial inner membrane electrochemical 
gradient [42, 43] (Figure 1-5). 
 
 
Mitochondria and Human Development 
 
 Mitochondria are dynamic organelles, the shape, size and number of which are 
highly variable and are controlled by fusion and fission [44]. The core mitochondrial 
fusion machinery in mammals consists of two related proteins mitofusins MFN1 and 
MFN2, which are essential for adjacent mitochondria during the fusion process [45-49]. 
Optic atrophy protein 1 (OPA-1), a mitochondrial dynamin-related protein, is another 
required molecule for fusion of the mitochondrial inner membranes, a function that 
consistent with its intermembrane space localization and inner membrane association [50, 
51]. Mitochondrial fission is dependent on the recruitment of a dynamin-related protein 1 
(DRP1) in mammals from the cytosol. DRP1 has been proposed to assemble into rings 
and spirals that encircle and constrict the mitochondrial tubule during fission [52].  
 
 Mitochondrial dynamics has been well known for several important biological 
functions. First, the balance between fusion and fission controls the shape, length, and 
number of mitochondria, which is highly dependent on the cell type and cellular energy 
status [53]. Second, fusion and fission processes allow mitochondria to exchange lipid 
membranes, mtDNAs and other intra-mitochondrial content, which helps maintain a 
healthy mitochondrial population [49, 54, 55]. Third, the dynamic characteristics of 
mitochondria help to distribute the mitochondria to specific subcellular compartment, 
which is extremely important in highly polarized cells, like neurons [56-58]. Due to these 
essential cellular functions, mitochondria are required for various biological processes, 
especially human development, and perturbations result in specific developmental 
defects.  
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Figure 1-5. Mitochondrial physiology 
Mitochondria lie at the nexus of most biosynthetic pathways, produce much of the 
cellular energy through oxidative phosphorylation (OXPHOS), regulate mitochondrial 
and cellular redox status, generate most of the reactive oxygen species (ROS), regulate 
Ca2+ concentrations and can initiate apoptosis by the activation of the mitochondrial 
permeability transition pore (mtPTP). The mtPTP can be activated by a decreased 
membrane potential, high-energy phosphates (such as ADP), a more-oxidized redox 
status, and/or increased mitochondrial matrix Ca2+ and ROS concentrations. Reducing 
equivalents and acetyl-CoA enter the mitochondrion via pyruvate and fatty acids. 
Pyruvate is transported through the mitochondrial inner membrane by the pyruvate 
transporter (PT), binds to pyruvate dehydrogenase (PDH), which may be membrane-
associated, and is oxidatively decarboxylated to produce acetyl-CoA. Inhibition of 
mitochondrial function results in pyruvate accumulation in the cytosol, where it can be 
reduced to lactate. Fatty acids are imported into the mitochondrion bound to carnitine. In 
the cytosol, fatty acids bound to CoA are transferred to carnitine, transported through the 
outer and inner mitochondrial membranes, and then transferred back to CoA for β-
oxidation. The transfer of fatty acyl groups between CoA and carnitine is mediated by the 
carnitine palmitoyltransferases (not shown). As a by-product of OXPHOS — the 
substrates and products of which are transported through the outer membrane by the 
voltage-dependent anion channels (VDACs) — mitochondria generate ROS by the 
donation of excess electrons from complexes I and III directly to O2 to generate 
superoxide anions (O2•−). Matrix O2•−, primarily from complex I, is dismutated to H2O2 
by the mitochondrial matrix Mn superoxide dismutase (MnSOD; also known as SOD2), 
while intermembrane-space O2•−, which is primarily from complex III, is dismutated by 
Cu/Zn superoxide dismutase (Cu/ZnSOD; also known as SOD1). H2O2 can be reduced to 
water by glutathione peroxidase using reduced glutathione as an electrondonor. Oxidized 
glutathione is reduced by glutathione reductase using NADPH as a reductant. In the 
presence of reduced transition metals, H2O2 can be reduced to hydroxyl radicals (•OH), 
which are the most reactive ROS. The mtPTP is a protein complex that is thought to 
include the translocator protein (TSPO; also known as PBR), an unknown inner-
membrane channel, adenine nucleotide translocators (ANTs) and the cyclosporine-A-
sensitive cyclophilin D (CYPD; also known as PPID), which are regulatory, in 
association with the BCL-2 pro- and anti-apoptotic family members. When activated, the 
mtPTP forms a channel between the inner and outer membranes, which short-circuits ΔP. 
This is associated with the aggregation of BAX and BAD in the mitochondrial outer 
membrane to form a megachannel. The megachannel releases pro-apoptotic proteins from 
the intermembrane space into the cytosol to initiate the degradation of the cellular 
proteins and DNA. AIF, apoptosis-inducing factor; CoA-SH, coenzyme A with a free 
sulphydryl group; CoQ, coenzyme Q10; ENDOG, mitochondrial endonuclease G; GPX, 
glutathione peroxidase; LDH, lactate dehydrogenase; OAA, oxaloacetate; SMAC, second 
mitochondria-derived activator of caspase; TCA, tricarboxylic acid. Reprinted with 
permission from Macmillan Publishers Ltd: Wallace DC. 2012. Mitochondria and cancer. 
Nature Reviews Cancer 12: 685-698.  
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 Previous studies revealed that mice deficient in either MFN1, MFN2 or OPA-1 
die in midgestation [54, 59-61]. They further showed that MFN2 lacking embryos have a 
severe and specific disruption of the placental trophoblast giant cell layer.  However, 
MFN1-deficient giant cell layers are normal but MFN1 deficient mice still die due to 
placental defects [54, 62]. A case of a newborn girl bearing a dominant-negative 
dynamin-related protein 1 (DRP1) allele has been reported. The patient died around 1 
month old and had a wide range of defects, such as microcephaly, abnormal brain 
development, optic atrophy and hypoplasia, persistent lactic academia, and elevated 
serum very-long-chain fatty acid [63].  
 
 Human reproduction, from oogenesis, fertilization to peri-implantation embryo 
development, has been suggested to be highly associated with the rate of mitochondrial 
replication as well as their activities. The optimal rate of oxygen consumption and fine 
regulation of aerobic and anaerobic respiration pathways are required for proper 
development [64].  
 
 
Mitochondria and Human Diseases 
 
Mitochondria are more than just a powerhouse of the cell. They have been 
reported to be intensively involved in the regulation of metabolism, cell-cycle control, 
development, antiviral responses and cell death (discussed earlier) [65]. Mitochondrion 
distinguishes itself from other organelles because it has its own mitochondrial DNA 
(mtDNA). The modern mammalian mtDNA has 13 polypeptide genes which encode 
essential components of OXPHOS. It also encodes the 12S and 16S rRNA genes and the 
22 tRNA genes required for mitochondrial protein synthesis [66]. Nuclear genes encode 
the remaining mitochondrial OXPHOS proteins, the metabolic enzymes, the DNA and 
RNA polymerases, the ribosomal components and the mtDNA regulatory factors [42]. 
Mutations on either mtDNA or mitochondrial function associated nuclear genes have 
been reported to be related to human diseases [42].  
 
 
Human Diseases Associated with MtDNA Mutations.  Mutations from either 
base substitutions or rearrangements of mtDNA causes human diseases. A missense 
mutation from a G to A transition in mitochondrial ND6 gene, which encodes a subunit of 
NADH dehydrogenase, has been associated with Leber’s hereditary optic neuropathy 
(LHON) [67]. Patients with LHON present with sudden-onset blindness in their early 
twenties because of the death of the optic nerve [67, 68]. Rearrangement mutations of 
mtDNA lead to diseases including chronic progressive external ophthalmoplegia (CPEO), 
Kearns-Sayre Syndrome (KSS), diabetes mellitus inherited from maternal side and 
deafness [69-72]. CPEO and KSS patients, for example, present with similar 
mitochondrial myopathy including ophthalmoplegia, ptosis and a subset of cardiac, renal, 
endocrine problems. 
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 Human Diseases from Mutations in Mitochondrial Function Related Nuclear 
Genes.  Mitochondrial diseases resulting from mutations in mitochondrial functions 
related nuclear genes share many of the clinical characteristics of mtDNA mutations. For 
instance, a mutation of the gene encoding one structural protein of electron transport 
chain (ETC) complex I has been reported in a young patient presenting hypotonia, mental 
retardation, seizure episodes, and basal ganglia degeneration [73]. Friedreich’s ataxia, an 
autosomal recessive disease, is an example that mutations in nuclear genes can affect 
OXPHOS or destabilize mtDNA indirectly. The encoded protein, frataxin, is imported to 
the mitochondrial inner membrane and performs function to transport iron out of the 
mitochondrion. When mutated, iron accumulates in the mitochondrial matrix, stimulating 
the overproduction of oxidative stresses. Patients present with cerebellar ataxia, 
peripheral neuropathy, and hypertrophic cardiomyopathy [74].  
 
 
Mitochondria and Cancer 
 
 Functional mitochondria are essential for cancer cell survival. Contrary to 
conventional opinions, although mutations affecting mitochondrial functions are common 
in cancer cells, they do not inactivate the energy and metabolic reactions but rather 
reprogram the mitochondrial bioenergetics and biosynthetic status to meet the 
requirements of the cancer cells [43]. And cancer therapies targeting mitochondria have 
been shown to be promising for cancer treatment [75].  
 
 
 MtDNA Mutations and Cancer.  Although functional mitochondria are essential 
for cancer cell survival, mtDNA mutations and/or reduced mtDNA copy numbers are 
common features of cancer cells, which suggests that altered mitochondrial bioenergetics 
and/or metabolism play an important role in tumor transformation and maintenance [43]. 
For example, the missense mutation of MTND3 gene, encodes ETC complex I subunit, 
has been reported to be linked with increased risk for breast cancer in African American 
women [76]. And another missense mutation of cytochrome c oxidase subunit 1 
(MTCO1) T6777C has been associated with epithelial ovarian cancer, along with several 
nuclear DNA mitochondrial genes variants [77]. A meta-analysis has revealed that many 
cancer-associated mtDNA mutations consistently and obviously inhibit OXPHOS, which 
might serve to either stimulate tumor transformation or promote cancer cell adaptation to 
the tumor environment [43].  
 
 
 Mitochondrial Signaling Pathway and Cancer.  Several hallmark cancer 
signaling pathways have been reported to reprogram mitochondrial physiology in order to 
promote tumor cell transformation, including c-MYC, K-RAS, PI3K and TP53 signaling 
pathways. For example, in addition to the various effects of oncogenic K-RAS signaling 
on proliferation, apoptosis and metabolism, it has also been reported to downregulate 
mitochondrial respiration and promote mitochondrial fission to support malignant 
transformation [78]. Another classical example should be PI3K-AKT-mTOR signaling 
pathway which has been shown to be overactive in many human cancers. The pathway in 
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cancer cells is often overstimulated by either oncogenic mutations in signaling kinases or 
loss-of-function mutations of tumor suppressor proteins like PTEN, which then activates 
the downstream effector mechanistic target of rapamycin (mTOR). mTOR, a core 
component of two distinct protein complexes mTORC1 and mTORC2, functions as a 
serine/ threonine protein kinase that regulates many biological activities, such as cell 
growth, proliferation, cell survival, protein synthesis, autophagy, and transcription [79]. 
PI3K-AKT-mTOR signaling pathway also inhibits carnitine palmitoyltransferase IA 
which is the rate limiting step for fatty acid oxidation and phosphorylates hexokinase II 
which is known to capture mitochondrial ATP and utilize it to convert glucose to 
glucose-6-phosphate. All these effects from activation of PI3K-AKT-mTOR pathway 
help the shift from oxidative phosphorylation to more glycolytic metabolism, which is 
more favorable for cancer cell transformation and proliferation [43]. 
 
 
 Oxidative Stress and Cancer.  Reactive oxygen species (ROS), in the form of 
superoxide (O2.-), hydroxyl free radicals (OH.), and hydrogen peroxide (H2O2), are 
produced from multiple physiological reactions, including electron transport through the 
ETC complex 1 and NAD(P)H oxidases. Mitochondria not only are the major 
contributors to cellular ROS production but also have multiple antioxidant strategies to 
neutralize ROS, such as superoxide dismutase (SOD2), glutathione, thioredoxin, and 
peroxiredoxins [78]. There are two faces of ROS biology: redox signaling and oxidative 
stress [80]. While redox signaling is essential for various cellular processes, such as 
proper cellular differentiation, proliferation, and tissue regeneration, high levels of ROS 
leads to oxidative stress which incur damage to DNA, protein or lipids, resulting in 
genomic instability to promote cancer cell transformation [80].  
 
 Well-known tumor suppressor p53 controls the expression of many antioxidant 
genes and it is been shown that tumor initiation in Trp53-/- mouse models can be 
successfully inhibited by antioxidant NAC supplementation in the diet, indicating a tumor 
suppressive function of p53 through regulating antioxidant and metabolism genes rather 
than apoptosis and cell cycle arrest [81-83]. Another example is that H2O2 has been 
suggested to inactivate tumor suppressor PTEN by oxidizing its cysteine residues and 
promoting the formation of a disulfide bond, which prevents PTEN from inhibiting PI3K 
pathway [84]. ROS-mediated regulation of oncogenic signaling has also been revealed to 
affect metastasis. As reported by Porporato et al. oxidation of cysteines in SRC increases 
its oncogenicity, facilitating tumor cell migration and metastasis in multiple tumor types, 
which can be blocked by a ROS scavenger [85].  
 
 While ROS play an essential role in activating proper mitogenic signals to 
promote cancer cell proliferation, survival and metabolic adaptation, too much ROS 
make cancer cells susceptible to oxidative stress-induced cell death. Therefore, cancer 
cells have to maintain ROS levels in a window which can stimulate proliferation without 
causing cytotoxicity [80]. The dependence on upregulated antioxidant pathways may act 
as an Achilles heel for cancer therapies. Combined therapy of glutathione and thioredoxin 
inhibitors has been shown to limit tumor growth in breast cancer models both in vitro and 
in vivo [78].  
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 Targeting Mitochondria for Cancer Therapy.  Cancer cells adopt an extensive 
metabolic reprogramming, which makes their mitochondria structurally and functionally 
different from their normal counterparts and renders them more susceptible to the 
mitochondrial targeted therapies [75]. Several selective mitochondria targeted strategies 
have already been shown to be promising on a variety of cancer models. Targeting 
mitochondrial permeability transition pore complex (MPTP) is one of the examples [86-
91]. Multiple compounds have been developed to act on the components of the MPTP to 
induce the outer mitochondrial membrane permeabilization and apoptosis. Another 
strategy is to design compounds that induce the overproduction of ROS or inhibit 
antioxidant systems. Motexafin gadolinium has been suggested to selectively accumulate 
in many types of cancers, exhibiting an overproduction of ROS and enhancing the in vivo 
response to radiotherapy on lung cancer as well as pediatric glioblastoma [92, 93]. There 
are now sufficient evidences suggesting shifting the balance of the ratio between pro-
apoptotic versus anti-apoptotic BCL-2 proteins primes cancer cells to die through 
MOMP-dependent apoptosis. One of the most well-recognized and best established 
example is BH3 mimetics, ABT-737, which specifically binds to BCL-2, BCL-XL and 
BCL-W and induces tumor cell death [94-97]. Last but not least, approaches reversing the 
hyperglycolytic state of cancer cells also have been shown to be successful in clinical 
trials. 2-deoxy-D-glucose (2DG), an inhibitor of glycolysis, has been revealed to 
significantly synergize with cisplatin on the cytotoxicity in treating human head and neck 
cancer cells [97]. 
 
 
CRISPR-Cas9 System for Genomic Editing 
 
In recent years, the development of genome engineering technologies, the process 
of making targeted genome modification in their endogenous context, allow researchers 
to rapidly and efficiently recapitulate biological functions or disease phenotypes of 
genetic mutations or epigenetic variants in cellular or animal models. It enables the direct 
correction of genetic or epigenetic defects in somatic tissues for genetically encoded 
disorders [98]. Generally speaking, directed genomic modification is achieved by 
targeting a genome-editing nuclease to the specific sequences in the genome, which 
recognize and cut at the specific site to generate double-strand breaks (DSBs). Generated 
DSBs can be further repaired by one of the two cellular endogenous DNA repair 
mechanisms: non-homologous end joining (NHEJ) or homology-directed repair (HDR) 
when a repair donor template DNA provided. NHEJ is highly efficient however error-
prone, which results in small insertions or deletions (indels) at the targeted locus and 
therefore leads to shift reading frame to generate nonfunctional proteins. By contrast, 
HDR-based gene repair can be used to create knockin sequences at targeted site when a 
donor template DNA containing homologous arms is delivered [99].  
 
There are four major strategies that are currently performed to introduce DSBs in 
the genome: meganucleases, zinc-finger nucleases (ZFNs), transcription activator-like 
effector nucleases (TALENs), and the clustered regularly interspaced short palindromic 
repeat (CRISPR)-Cas system [100-103]. Meganucleases target various sequences and 
they are considered as the most specific strategy due to the recognition sequences are 
 16 
long enough to occur only with a very low chance. However, the requirement that DNA 
recognition and cleavage sites need to be linked closely limits the broad application of 
those nucleases [101]. ZFNs are generated via the fusion of a zinc-finger DNA binding 
domain with the cleavage domain called FokI nuclease that acts as a dimer [102]. 
TALENs are composed of the DNA binding domain called transcription activator-like 
effector (TALE) and a FokI nuclease [103]. All three, meganucleases, ZFNs, and 
TALENs, create DNA targeted sequence recognition specificity via protein-DNA 
interaction and require labor- or time-consuming protein engineering or assembly [99]. 
 
 RNA-guided endonuclease Cas9 from the microbial adaptive immune system 
CRISPR has been developed in the recent 5 years and provides a highly sensitive and 
precise system for achieving targeted mutagenesis in eukaryotic cells with its ease of 
customization and high efficiency. The Cas9 nuclease is paired and targeted to genomic 
DNA by a guide RNA consisting of a 20-nucleotide sequence and a scaffold with the 
guide sequence required to be directly upstream of a 5’-NGG adjacent motif called PAM 
motif [104] (Figure 1-6). Then, Cas9 endonuclease induces a double strand break around 
3 bp upstream of the PAM motif. DSBs can be repaired by either NHEJ pathway, which 
results in random indels to make a gene knockout, or homologous recombination, which 
allows for high fidelity and precise editing when a repair template is provided [104] 
(Figure 1-7). 
 
 CRISPR-Cas9 system has enabled efficient and accelerated generation of 
transgenic models to allow for recapitulating genetic mutations found in patient 
populations, which facilitates the study of disease mechanisms and therapeutic targets 
[98, 105]. Researchers have also applied this technology to engineer isogenic ES or iPS 
from patients with specific mutations and then induce those stem cells to differentiate and 
recapitulate the disease development models and screen for therapeutic targets [106]. 
Genome-wide loss-of-function screening can be performed by mass synthesis and 
delivery of guide RNA libraries to disrupt thousands of genomic elements in parallel to 
study candidate genes affecting phenotypes [107, 108]. In addition to a research tool that 
has been widely used, CRISPR-Cas9 system is also a potential strategy for therapeutic 
purpose. For example, some monogenic diseases such as cystic fibrosis, sickle-cell 
anemia, etc. have loss-of-function mutations due to small deletions or replacements that 
can be corrected by Cas9-induced gene repair [98, 106]. Other than repairing underlying 
mutations, Cas9-mediated NHEJ repair can be utilized for introducing protective 
mutations, such as Cas-9-induced inactivation of the CCR5 receptor, a co-receptor 
required for HIV incorporation [109]. Despite many of the advantages, challenges need to 
be addressed, such as finding the efficient delivery systems, reducing the off-target 
effects, and monitoring the long-term safety issues [98]. 
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Figure 1-6. Schematic of the RNA-guided Cas9 nuclease 
The Cas9 nuclease from S. pyogenes (in yellow) is targeted to genomic DNA (shown for 
example is the human EMX1 locus) by a sgRNA consisting of a 20-nt guide sequence 
(blue) and a scaffold (red). The guide sequence pairs with the DNA target (blue bar on 
top strand), directly upstream of a requisite 5’-NGG adjacent motif (PAM; pink). Cas9 
mediates a DSB around 3 bp upstream of the PAM (red triangle). Reprinted with 
permission from Macmillan Publishers Ltd: Ran FA, Zhang F. 2013. Genome 
engineering using the CRISPR-Cas9 system. Nature Protocol 8: 2281-2308. 
 
 
 
 
Figure 1-7. DSB repair promotes gene editing 
DSBs induced by Cas9 (yellow) can be repaired in one of two ways: In the error-prone 
NHEJ pathway, the ends of a DSB are processed by endogenous DNA repair machinery 
and rejoined, which can result in random indel mutations at the site of junction. Indel 
mutations occurring within the coding region of a gene can result in frameshifts and the 
creation of a premature stop codon, resulting in gene knockout. Alternatively, a repair 
template in the form of a plasmid or single-stranded DNA oligonucleotides (ssODN) can 
be supplied to leverage the HDR pathway, which allows high fidelity and precise editing. 
Single-strand nicks to the DNA can also induce HDR. Reprinted with permission from 
Macmillan Publishers Ltd: Ran FA, Zhang F. 2013. Genome engineering using the 
CRISPR-Cas9 system. Nature Protocol 8: 2281-2308.  
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CHAPTER 2.    MATERIALS AND EXPERIMENTAL PROCEDURES 
 
 
Mice 
 
 Mcl-1flox/flox CreERT2, Mcl-1flox/WT CreERT2 and Mcl-1flox/flox ESCs were generated at 
E3.5 from the C57BL/6 mice with respective genotypes. CreERT2 is a tamoxifen inducible 
Cre recombinase system. To induce deletion, five doses of tamoxifen emulsified in 
sunflower oil vehicle (Sigma) were performed through gavage (1 mg per dose; Sigma). 
All conditional mice were on a C57BL/6 background and littermates were used as 
controls. Nu/J mice used for teratoma formation assays were obtained from Jackson 
Laboratory. C57BL/6J mice (Jackson Laboratory) were used for zygote injections. All 
mice were maintained in accordance with the Institutional Animal Care and Use 
Committee of St. Jude Children’s Research Hospital as required by the U.S. Animal 
Welfare Act and National Institutes of Health Policy for proper care and use of laboratory 
animals for research.  
 
 
Cells and Cell Culture 
 
 The 129/SvJ ES cell line F12, derived by Jacqueline Surtel (St. Jude Children’s 
Research Hospital) was routinely cultured on tissue-culture treated dishes (Corning) in 
ESCs medium, consisting of 90% glucose-free Dulbecco’s modified Eagle’s medium 
(DMEM, Lonza), 10% fetal bovine serum (FBS, Hyclone), 100 U/ml penicillin, 100 
ug/ml streptomycin, 2 mM L-glutamine (all from Invitrogen), 0.1 mM mercaptoethanol 
(Gibco), and 103 U/ml recombinant mouse leukemia inhibitory factor (LIF from 
Millipore). Mcl-1-conditional ESCs were derived at E3.5 from Mcl-1-conditional mice 
breedings described previously. Once plugs were observed at E0.5, mice uteri were 
dissected under the microscope and blastocysts were flushed. Inner cell masses (ICMs) 
were separated from the whole blastocysts and transferred onto pre-coated irradiated 
MEFs. After expansion, single cell clones were picked for genotyping. Mcl-1 conditional 
ESCs were grown in the same medium as F12 ESCs. 
 
SV40-transformed Mcl-1 conditional mouse embryonic fibroblasts (MEFs) have 
been previously described [17]. To induce Mcl-1 deletion, the MEFs were treated for 48 
hours with 100nM 4-hydroxy-tamoxifen (Sigma) in culture medium. HEK 293T cells 
were obtained from American Type Culture Collection. Arfnull GFP MEFs, derived by Dr. 
Frederique Zindy (St. Jude Children’s Research Hospital), were exposed to 4000 rads 
from a γ-radiation source and used as stromal cells. All MEFs, HEK 293T cells and 
irradiated MEFs were grown in 90% glucose-free DMEM (Invitrogen) supplemented 
with 10% FBS (Gibco), 100 U/ml penicillin, 100 ug/ml streptomycin, 2 mM L-glutamine 
(all from Invitrogen), and 0.1 mM mercaptoethanol (Gibco).  
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Plasmids, Expression Constructs, and Generation of Mutants 
 
 All Mcl-1 constructs were generated according to mouse Mcl-1 cDNA. The 
mutants Mcl-1 cleavage site (CS) 10, 11 and Mcl-1 CS 33, 34, in which isoleucine, lysine 
and leucine, valine were replaced by aspartic acid, were derived by site-directed 
mutagenesis (Stratagene). The mutant Mcl-1 Matrix was generated by fusing amino acids 
1-58 of N. crassa ATP-synthase to Mcl-1 N-terminal 34 amino acids truncated mutant. 
Mcl-1 ATG1 and M92 were derived by mutating the first start codon of Mcl-1 to TGA 
stop codon and N-terminal 91 amino acid truncation, respectively.  
 
 
Ecotropic Retroviral Production and Cell Transduction 
 
 Ecotropic retroviruses were produced by co-transfection of packaging plasmids 
(pMD-old-Gag-Pol and pCAG4-Eco) and retroviral expressing plasmids to HEK 293T 
cells by using FuGene6 (Roche Applied Bioscience). Collected viruses were filtered and 
applied on either ESCs or Mcl-1 conditional MEFs together with 10 ug/ml polybrene 
(PB, AmericanBio).  
 
 
Crispr-Cas9 System for Genomic Targeting 
 
 Nine guide RNAs were designed close to Mcl-1’s genomic start codon and amino 
acid 10 isoleucine, 11 glycine and paired with the DNA target directly upstream to a 5’-
NGG as following: 
 
 CrRNA-F1, 5’- GTCCGACCATGTTTGGCCTG -3’; 
CrRNA-F2, 5’- GTTTGGCCTGCGGAGAAACG -3’; 
CrRNA-F3, 5’- GATGACTTGAACCTGTACTG -3’; 
CrRNA-F4, 5’- GCCAGCCTCGGCGCGGGCGG -3’; 
CrRNA-R1, 5’- GTCGGACGCCGCAGGCTGAG -3’; 
CrRNA-R2, 5’- GTTTCTCCGCAGGCCAAACA -3’; 
CrRNA-R3, 5’- ACCGCCGCCCGCGCCGAGGC -3’; 
CrRNA-2F, 5’- GCGGGCGGCGGTTCTCCGGC -3’; 
CrRNA-2R, 5’- GGCTGGCGCCGCCGCAGTAC -3’. 
 
 Then, each of the guide RNA was cloned into the all-in-one Cas9 (BB)-2A-GFP 
(Addgene plasmid ID: 48138) through BbsI enzyme site and validated by sequencing 
with a universal U6-forward primer:  
 
5’-GAGGGCCTATTTCCCATGATTCC-3’.  
 
Repair templates single-stranded DNA oligonucleotides (ssODNs) containing 5’ 
and 3’ homologous arms, amino acids 10 aspartic acid, 11 aspartic acid mutations as well 
as the mutated CRISPR-Cas9 binding sites were also designed by either symmetric or 
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asymmetric strategies and synthesized through IDT (Integrated DNA Technologies) for 
making cleavage site amino acid 10, 11 knock-in (CS10,11 KI) mutagenesis as following:  
 
Symmetric ssODN CS10,11 F3M, 5’- CCT GCG GCG TCC GAC CAT GTT 
TGG CCT GCG GAG AAA CGC GGT CGA TGA CCT CAA TCT ATA CTG CGG 
CGG CGC CAG CCT CGG CGC GGG CGG CGG TTC TCC G -3’; 
Asymmetric ssODN CS10, 11 F3M, 5’- CCT CGC GCC GCG CCT TGG CCT 
CCT CGG CCA CCA GGC GCG CCC CTG CCG GAG AAC CGC CGC CCG CGC 
CGA GGC TGG CGC CGC CGC AGT ATA GAT TGA GGT CAT CGA CCG CGT 
TTC TCC GCA GGC CAA ACA TGG TCG GAC G -3’; 
 Symmetric ssODN CS10,11 R2M, 5’- TTC CCC TCA GCC TGC GGC GTC 
CGA CCA TGT TTG GCC TGC GGC GCA ATG CGG TCG ATG ACT TGA ACC 
TGT ACT GCG GCG GCG CCA GCC TCG GCG CGG GCG G -3’; 
 Asymmetric ssODN CS10, 11 R2M, 5’- TTC CGC CTG CCT CCG GTC TGG 
AGT CGC GGC CTT CCC CGC TCC TTC CCC TCA GCC TGC GGC GTC CGA 
CCA TGT TTG GCC TGC GGC GCA ATG CGG TCG ATG ACT TGA ACC TGT 
ACT GCG GCG GCG CCA GCC TCG GCG CG -3’.  
 
Embryonic stem cells (ESCs) F12 were transfected with each guide RNA 
containing all-in-one plasmid as well as ssODNs repair template. 48 hours after 
transfection, ESCs were sorted for GFP positive cells. After sort, 20,000 cells were 
seeded in 10 centimeter (cm) dish and growing as single cell clones. The leftover pool 
cells from each individual guide RNA were screened first by T7E1 surveyor nuclease 
digestion as well as by immunoblotting. After single cells grew out, they were screened 
by both Sanger sequencing and immunoblotting.  
 
 
Surveyor Nuclease Digestion 
 
 DNA was extracted from ESCs for each guide RNA leftover pools. PCR was 
performed to amplify targeted Mcl-1 amplicons by using the following primers:  
 
 Mcl-1 forward primer, 5’- AACGGCCTTCCTCACTCCTGACTT -3’; 
 Mcl-1 reverse primer, 5’- AGTAGCGCGAGATGATCTCCAGCGA -3’. 
 
 Further the PCR amplified targeted sequences were denatured and re-hybridized. 
PCR reactions were subjected to endonuclease T7E1 digestion which would recognize 
the heteroduplexes formed by either wild-type and mutant sequences or two different 
mutant amplicons. The final PCR reactions treated in the absence or presence of T7E1 
were evaluated by agarose gels.  
 
 
Immunoblotting, Co-immunoprecipitation, and Antibodies 
 
 Cells or tissues were lysed in radioimmunoprecipitation assay (RIPA) buffer (50 
mM Tris-HCL at pH 7.4, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1% sodium 
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deoxycholate, 0.1% SDS) containing protease inhibitors (Cat: 11836145001, Roche) on 
ice for 30 minutes. Lysates were then collected by centrifugation and protein 
concentrations were measured by BCA assay (Pierce) with standard curve. 20 
micrograms (ug) of each protein samples was loaded on 10% NuPAGE Bis-Tris gels 
(Invitrogen) and MOPS SDS served as the trailing ion in the running buffer. For co-
immunoprecipitation assays, whole cell lysates (WCLs) were collected and coupled with 
anti-BIM rat monoclonal antibody (Millipore) for one hour, and then precipitated with 
protein A/G-plus agarose (Santa Cruz Biotechnology). Immunocomplexes and post-
immunoprecipitated supernatants were subjected to 10% NuPAGE Bis-Tris gels 
(Invitrogen), transferred to PVDF (Millipore) and developed by using Western Lightning 
ECL Pro (Perkin Elmer) on a LI-COR Odyssey (LI-COR, NB). The following antibodies 
were used: anti-MCL-1 (Rockland Immunochemical), anti-Actin (Millipore), anti-OPA-1 
(BD Biosciences), anti-MnSOD (BD Biosciences), anti-BIM (BD Biosciences), anti-
mBCL-2 (Clone 3F11, gift of S. Korsmeyer), anti-hBCL-2 (Clone 6C8, gift of S. 
Korsmeyer), anti-BAX (Millipore), anti-ATP5B (Santa Cruz Biotechnology), anti-
Caspase 3 (Cell Signaling Technology) and anti-PARP (Cell Signaling Technology).  
 
 
Genotyping and Sanger Sequencing 
 
 Genomic DNA of single ES colonies or tail tissues of individual pups were 
extracted in 100 mM Tris-HCl at pH 8.3, 100 mM NaCl, 5 mM EDTA, 1% Triton X-100, 
and 100 ug/ml proteinase K. Samples were incubated overnight at 55°C and 85°C for 45 
minutes. Debris were removed by 13,000 rpm centrifugation for 10 minutes. Genomic 
DNA was amplified by using Mcl-1 forward primer 5’- AACGGCCTTCCTCACTCC 
TGACTT -3’ and Mcl-1 reverse primer, 5’- AGTAGCGCGAGATGATCTCCAGCGA -
3’. PCR products were purified (Qiagen PCR purification kit) and subjected to Sanger 
sequencing by using the same Mcl-1 forward primer. Homozygous mutations were 
determined by comparison to mouse Mcl-1 genomic sequences and heterozygous 
mutations were determined by filtering out the known sequence of the wild-type allele.  
 
 
Mass Spectrometry Identification 
 
 MCL-1 wild-type (WT) and mutant 30 kD ESCs around 5 million each were 
washed with PBS and re-suspended in 0.5 ml hypotonic buffer (20 mM Tris HCl at pH 
7.4, 10 mM MgCl2 containing protease inhibitors described previously), and then 
homogenized by brief sonication. After short centrifugation at 800g, the supernatant was 
taken for ultracentrifuge at 180,000g for 10 min at 4°C. The pellets were dissolved in 50 
ul 1% Triton X-100 in PBS containing PIC and centrifuged at 20,000g for 3 minutes. 
 
 The supernatant was collected and separated by SDS-PAGE. The bands were cut 
from the predicted regions, and then digested by 12.5 ng/ul trypsin in 50 mM NH4HCO3 
at pH 8.5. The final peptide samples were loaded to C18 column (75 uM internal 
diameter, 10 cm long, 1.9 um resin beads), eluted at 15-40% buffer B gradient (buffer A: 
 22 
0.2% formic acid, 5% acetonitrile; buffer B: 0.2% formic acid, 95% acetonitrile) at 300 
nl/min for 6 hours on LTQ Orbitrap Velos (Thermo Scientific).  
 
 
Embryoid Body Formation 
 
 Embryoid bodies (EBs) were generated by separating the undifferentiated mouse 
ESCs and resuspending 300 cells into 50 ul hanging drops. Two days later, aggregates 
were collected and transferred to ultralow attachment dishes with EB culture medium, 
consisting of 90% DMEM (Lonza), 10% FBS (Hyclone), 100 U/ml penicillin, 100 ug/ml 
streptomycin, 2 mM L-glutamine (all from Invitrogen), and 0.1 mM mercaptoethanol 
(Gibco). The medium was changed every other day. EBs were collected by either day 4 
or day 10 for further analysis.  
 
 
Cryosectioning and Immunofluorescent Staining of Embryoid Bodies 
 
 Collected embryoid bodies (EBs) were precipitated and mounted in tissue 
freezing medium (Triangle Biomed), then saved at -80°C. Cut 10 um thick tissue sections 
by using a cryostat (Microm HM 505) onto the microscope slides (Fisher Scientific). 
Sections were air dried for 30 minutes at room temperature (RT) and the EBs fixed on the 
glass cover slip in 4% paraformaldehyde (PFA) in PBS supplemented with 0.1% Triton 
X-100 for 15 minutes at RT, followed by permeabilization with 0.1% Triton X-100 in 
PBS for 5 minutes at RT. Cells were blocked with 10% goat serum in PBS. All primary 
antibodies were diluted in 3% goat serum in PBS added to slides and incubated overnight 
at 4°C. Cells were treated with fluorescently coupled secondary antibody diluted in 3% 
goat serum in PBS, goat anti-mouse or goat anti-rabbit (Life Technologies) and were 
incubated for 1 hour at RT. Glue containing DAPI (ProLong Gold Antifade Mountant, 
Thermo Fisher Scientific) was added onto the EBs and covered by a glass. The glue was 
allowed to dry and all images were captured by using microscopy (Zeiss Axioskop II 
Plus).  
 
 
RNA Isolation and Quantification 
 
 RNA was extracted from ESCs with TRIzol (Ambion) and reverse transcribed by 
using SuperScript III first-strand synthesis kit (Invitrogen). Fast real-time PCR with fast 
SYBR green (Bio-Rad) detection was performed by using QuantStudio 7 Flex (Life 
Technologies). And the following primers were used:  
 
 mSox-2 forward: 5’- GGTTACCTCTTCCTCCCACTCCAG -3’; 
 mSox-2 reverse: 5’- TCACATGTGCGACAGGGGCAG -3’; 
 mOct-4 forward: 5’- ATGGCATACTGTGGACCTCA -3’; 
 mOct-4 reverse: 5’- AGCAGCTTGGCAAACTGTTC -3’; 
 mSox7 forward: 5’- GACACCTTGGATCAGCTAAGCC -3’; 
 mSox7 reverse: 5’- CCTCCAGCTCTATGACACACTG-3’; 
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 mFgf-5 forward: 5’- AAAGTCAATGGCTCCCACGAA -3’; 
 mFgf-5 reverse: 5’- GGCACTTGCATGGAGTTTTCC -3’; 
 mmHox-4 forward: 5’- TGGCGGCACAAGCAGACGAAAG -3’; 
 mmHox-4 reverse: 5’- GTGAGGTTCACCCGACGTGCGAGA -3’; 
 mIhh forward: 5’- ACGTGCATTGCTCTGTCAAGT -3’; 
 mIhh reverse: 5’- CTGGAAAGCTCTCAGCCGGTT -3’; 
 mGapdh forward: 5’- TGTGTCCGTCGTGGATCTGA -3’; 
 mGapdh reverse: 5’- CCTGCTTCACCACCTTCTTGA -3’. 
 
 Double delta Ct analysis was used to calculate the mRNA levels. The assay was 
done in triplicate for each sample.  
 
 
Teratoma Formation Assay 
 
 For teratoma induction, one million of ESCs were injected intramuscularly into 
immunodeficient nude mice. For Mcl-1flox/flox CreERT2 ESCs, tamoxifen or vehicle gavage 
was performed one week after ESCs injection, five days in a row, to delete the 
endogenous MCL-1. Tumor growth was observed and palpated every day. When any of 
the tumors reached around twenty percent of surface area of the recipients, all the 
teratomas were harvested at the same time. Images of teratomas were taken and pieces of 
teratoma tissues were cut for histology, PCR or immunoblot analysis.  
 
 
Histology 
 
 Teratoma tissues were fixed in 10% neutral buffered formalin, embedded in 
paraffin and cut into 4-um thickness of sections by using HM500M cryostat (Microm). 
The embedded sections were stained by hematoxylin and eosin (H&E) stain. Three germ 
layer tissues of teratoma samples were reviewed by the pathologist Dr. Jerold Rehg at St. 
Jude Children’s Research Hospital.  
 
 
Cell Death Assay 
 
 F12 ESCs or Mcl-1flox/flox CreERT2 MEFs stably expressing murine stem cell virus 
MSCV-puro vector, WT MCL-1, ATG1 or M92 grown in the presence of tamoxifen for 
48 hours were treated with staurosporine at increasing doses for 16 hours (Calbiochem). 
Cell viability was determined by Annexin-V-APC and propidium iodide (PI) (BD 
Biosciences) staining through flow cytometry FACSCantoII (BD Biosciences). 
 
 
Subcellular Fractionation and Proteolysis of Heavy Membrane Fraction 
 
 ESCs or MEFs were swollen in ice-cold mitochondria isolation (MIB) buffer (200 
mM mannitol, 68 mM sucrose, 10 mM HEPES-KOH at pH 7.4, 10 mM KCl, 1 mM 
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EDTA, 1 mM EGTA, 0.1% BSA) containing protease inhibitor cocktail (PIC) for 30 
minutes and then homogenized 30 times with a 30 gauge needle. The non-lysed cells and 
nuclei were sedimented by centrifugation at 600g for 10 minutes and disposed. The 
collected supernatant was centrifuged at 5,500g for 15 minutes and the pellet was the 
heavy membrane fraction. The supernatant again was centrifuged at 100,000g for 30 
minutes and the soluble fraction contained the purified cytosolic proteins.  
 
 The isolated heavy membrane (HM) fraction, mainly mitochondria, was measured 
by Bradford assay for protein concentration. HM (40 ug) were set up with the following 
treatment: proteinase K (0.2 mg/ml), 20 mM KCl (osmotic shock), proteinase K (0.2 
mg/ml) plus 20 mM KCl (osmotic shock), 1% SDS (detergent for membrane 
solubilization) for 60 minutes on ice. Proteins were further precipitated by 
tricholoroacetic acid (TCA) (Sigma) and subjected to immunoblotting analysis.  
 
 
Zygote Injection 
 
 Freshly fertilized E0.5 post-coital single cell embryos (zygotes) were obtained 
from freshly weaned ovulated C57BL/6J mice. Recovered zygotes were cultured until 
both pronuclei were microscopically visible. Approximately 150-200 zygotes were 
transferred to a microdrop of M2 medium (Sigma-Aldrich) on a microinjection slide 
overlaid with mineral oil and the slide was placed on an inverted microscopy. 
Microinjection pipettes were filled with 100 ng/ul guide RNA with scaffold, 50 ng/ul 
Cas9 mRNA and 200 ng/ul ssODN. Each embryo was held with light suction by a 
holding pipette and rotated until one of the two pronuclei was visible. Then, mRNA 
mixture was injected into the cytoplasm and DNA into one pronucleus. Successful 
injection of a few picoliters (pl) of solution was observed by the visible swelling of the 
pronucleus or presence of a jet stream in the cytoplasm. Microinjected zygotes were 
surgically transferred to the infundibula of 0.5-day-post-coital pseudopregnant foster 
mothers on the same day, 20 to 25 zygotes per recipient. Full-term pups were obtained by 
natural labor about 19 days later. All the zygote microinjection procedures were carried 
out by the transgenic core facility at St. Jude Children’s Research Hospital.  
 
 
DNA Deep Sequencing 
 
 DNA of toes from zygote injection founders was collected. Endogenous Mcl-1 
amplicons of exon 1 around start codon were amplified by the same Mcl-1 forward and 
reverse primers described earlier. Amplicons from different samples were mixed and 
barcoded by another round of PCR using a Nextera Index Kit and the adaptor primers 
used were Nextera forward 5’- TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG -
3’ and reverse 5’- GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG -3’. The 
library prepared from the final PCR products of indexed samples was subjected to a 300 
bp-paired-end sequencing with Illumina Miseq for the targeted region. After quality 
control, reads of each sample were aligned to the sequences of targeted region and 
compared with the same sequencing run generated from control sample with more than 
 25 
10,000x depth of coverage. After deep sequencing, an in-house Perl script was used to 
analyze and summarize the allele frequencies of Mcl-1 variants. 
 
 
Microarray Analysis and GSEA 
 
 Affymetrix Mouse Gene 2.0 ST arrays were used to assay gene expression 
analysis from RNA samples. Mcl-1flox/flox CreERT2 ESCs treated with tamoxifen for 48 
hours were statistically tested by unequal variance t test to the DMSO control (3 
replicates). Gene set enrichment analysis (GSEA) (version 2.3.3) was performed by 
comparing Mcl-1flox/flox CreERT2 ESCs treated with tamoxifen versus DMSO control.  
 
 
Statistics 
 
 Growth curves significance was calculated by using the two-tailed Student t test 
and p values are denoted in the figure legends. GSEA comparing Mcl-1flox/flox CreERT2 
ESCs treated with tamoxifen versus DMSO control was statistically calculated by 
unequal variance t test.  
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CHAPTER 3.    RESULTS 
 
 
CRISPR-Cas9 Targeting of Genomic Mcl-1 to Generate Mcl-1 Mutants 
 
 To target genomic Mcl-1 by CRISPR-Cas9, we designed 9 individual guide RNAs 
around the start codon of Mcl-1 and each of the gRNAs was directly upstream of a 
requisite 5’-NGG. A single-stranded DNA oligonucleotide (ssODN) containing both 5’ 
and 3’ homologous arms and amino acids 10, 11 mutations was provided as a repair 
template. Our preliminary data suggested that mutagenesis of amino acids 10, 11 from 
isoleucine, glycine to aspartic acid abrogates MCL-1’s importation to the mitochondrial 
matrix, only maintaining its anti-apoptotic species. For in vitro targeting, we chose 
embryonic stem cells (ESCs) because ESCs form self-renewing compact colonies from 
single cells, which allows us to screen individual mutation, and ESCs are pluripotent cells 
that can differentiate to three germ cell layers: ectoderm as neurons, mesoderm as 
cardiomyocytes, and endoderm like gut tissues. More importantly, when injected into 
blastocysts, those blastocysts can be transferred into foster mothers to make chimeric 
recipient pups.  
 
 We transfected the F12 ESCs with our all-in-one CRISPR-Cas9-GFP plasmid as 
well as an ssODN containing amino acids 10, 11 mutations as the repair template, and 
sorted GFP positive cells. The CRISPR-Cas9 transfected GFP positive cells were seeded 
at low density 20,000 cells in 10 cm dish to grow as single cell clones. The left over 
targeted pool of cells were first analyzed by Surveyor endonuclease assay T7E1, which is 
an enzyme mismatch cleavage assay used to detect small mismatches, insertions or 
deletions. By comparing the amplicons in the presence or absence of T7E1, WT control 
showed no observable cleaved band (Figure 3-1A). Among the 9 individual crRNAs as 
well as a paired CRISPR-RNA (crRNAs), four of them, crRNA-F3, crRNA-R1, crRNA-
R2, crRNA-R3, showed obvious cleavages, indicating the presence of mutant DNAs. The 
mutation efficiencies were roughly estimated by the densitometry of decreased full-length 
band in the presence of T7E1 divided by the full-length band in the absence of T7E1 
enzyme (Figure 3-1A). Immunoblotting of the targeted pool cells showed reduced 
expression levels of full-length MCL-1 in crRNA-F3, crRNA-R1, crRNA-R2, and 
crRNA-R3, which is consistent with T7E1 assay (Figure 3-1B).  
 
 After the single cells grew out, we extracted the DNA and performed PCR for the 
amplicons from ESC clones from the most efficient four gRNAs. All successfully 
amplified fragments were sent for Sanger sequencing. Total mutation efficiencies ranged 
from 75% to 96.2% among the four gRNAs and bi-allelic mutation efficiencies were 
from 31.2% to almost 90% (Table 3-1). MCL-1 amino acids 10, 11 replacement mutant 
(CS10, 11 MCL-1) was not generated during our in vitro screening. We hypothesize is that 
the bi-allelic mutation efficiency was high and that cells were inclined to repair through 
the NHEJ pathway. 
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Figure 3-1. Pool validation of CRISPR-Cas9 targeting efficiency 
(A) PCR amplified targeted amplicons from each guide RNA pool ESCs were treated in 
the absence or presence of endonuclease T7E1. The mutation efficiency was calculated 
by the ratio of decrease full-length band density divided by untreated full-length band 
density estimated by densitometry. (B) Expression level of full-length MCL-1 in each 
guide RNA pool ESCs by immunoblotting. α-Actin was used as loading control.  
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Table 3-1. Summary of F12 ESCs transfected with CRISPR-Cas9 targeting on 
genomic Mcl-1 
 
CRISPR 
RNA 
Clones 
Screened 
Clones 
Amplified 
Total 
Efficiency 
Mono-allelic 
Efficiency 
Bi-allelic 
Efficiency 
crRNA F3 48 35 90% 10% 80% 
crRNA R1 48 25 75% 43.8% 31.2% 
crRNA R2 48 16 75% 33.3% 41.7% 
crRNA R3 48 27 96.2% 7.7% 88.5% 
 
DNAs extracted from single ESC clones from the four highest mutation efficiency guide 
RNA groups (F3, R1, R2, and R3), validated from previous T7E1 and pool 
immunoblotting. DNAs were amplified for the CRISPR-Cas9 targeted amplicons and 
sent for Sanger sequencing. Homozygous mutations were determined by comparison to 
mouse Mcl-1 genomic sequences. Heterozygous mutations were determined by filtering 
out the known sequence of the wild-type allele. 
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 At the protein level, large deletion on both alleles disrupting start codon of Mcl-1 
all generated a truncated form of MCL-1 rather than a complete knock out. Full-length 
MCL-1 is around 38 kD and the truncated mutant was around 30 kD (Figure 3-2A). To 
reveal whether 30 kD starts from the second methionine initiation, we performed mass 
spectrometry (MS) N-terminal identification. Protein lysates of the enriched heavy 
membrane from Wild-type (WT) and 30 kD mutant ESCs were loaded on SDS-PAGE gel 
and the gel bands around 38 kD for WT and 30 kD for mutant ESCs were cut for 
identification (Figure 3-2B). The proteolytic fragments of the N-terminus were identified 
according to their mass-to-charge ratio. The data indicate that when disrupting the start 
codon of Mcl-1 on both alleles, MCL-1 will initiate translation through the second 
methionine (M92) and produce a 30 kD truncated protein (Figure 3-2C and D). 
 
 
Mutant ESCs Show a “Sick” Phenotype and Fail to Differentiate to Broad Lineages 
 
 Phenotypically, when seeding equal number of cells during culture, WT ESCs 
presented as big, healthy clones. As WT control we used the CRISPR-Cas9 targeted GFP 
negative sorted cells (Figure 3-3). However, 30 kD ESCs presented as much smaller 
clones with low attachment (Figure 3-3).  
 
 To evaluate the pluripotency as well as the differentiation capacity of the mutant 
ESCs, embryoid body (EB) assay was performed. During the routine culture of ESCs in 
the presence of leukemia inhibitory factor (LIF) which is used to maintain ESCs’ 
pluripotency, ESCs present as typical compact clones with undifferentiated cells. EBs are 
generated by separating the undifferentiated ESCs into hanging drops and transferred to 
ultralow attachment dishes lacking LIF. Cells will aggregate at the bottom of the drop. In 
the absence of LIF, the well-organized EBs will spontaneously differentiate toward the 
different germ lineages. They begin with a single extraembryonic endoderm layer which 
is BMI-1, DAB-2 positive and extraembryonic endoderm surrounds the pluripotent 
epiblast cells which are OCT-4 positive. Other cells within the inner cell mass are 
composed of three germ cell lineages, ectoderm, mesoderm, endoderm, as well as the 
apoptotic cells.  
 
In response to the differentiation signals (absence of LIF), EBs often form cystic 
cavities, where the interior cells undergo apoptosis while the other cells migrate as well 
as differentiate to specific lineages. Therefore, cavitation is the relatively early event and 
the characteristic feature of the EBs undergoing differentiation. On day 4, we started to 
observe the beginning of a cavity in the WT control EBs, represented by the bright, 
transparent regions. This was not found among the different EBs with 30 kD MCL-1 
protein (Figure 3-4). In order to define whether it is a delay or a completely failed 
differentiation, EBs were harvested at day 10 and immunofluorescent (IF) staining was 
performed on the cryosections of EBs to look at the markers for extraembryonic 
endoderm as well as epiblast cells. The IF data suggested that DAB-2, an extraembryonic 
endoderm marker, was expressed at the periphery of WT EBs, which surrounded the  
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Figure 3-2. Mass spectrometry N-terminal identification of mutant MCL-1 
(A) Immunoblotting of the enriched membrane protein fraction from wild-type MCL-1 
and mutant 30 kD MCL-1 mouse ESCs was performed to verify MCL-1 protein existence 
and its localization against the protein ladder (BenchMark, Life Technologies). (B) SDS-
PAGE of these two samples to excise the gel bands (boxed) for identification by mass 
spectrometry (MS). (C) The amino acid sequence of mouse MCL-1. The traditional and 
the hypothetical methionine “M” at the translation initiation sites were highlighted. The 
peptide to be identified by MS was underlined. (D) The mass spectrum of the N-terminal 
peptide of the mutant 30 kD MCL-1. Product ions (fragments from the peptide) were 
indicated by arrows with measured mass-to-charge ratio (m/z). All matched product ions 
were also shown in the peptide. Note: the methionine of this N-terminal peptide was 
removed, and the next amino acid alanine was acetylated.   
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Figure 3-3. Mutant ESCs present a “sick” phenotype in culture 
Wild-type ESCs and different lines of 30 kD mutant ESCs (Cl 005, Cl 016, Cl 061, Cl 
071, and Cl 098) were seeded as equal number of cells in culture. The phenotype of cells 
were observed and captured by inverted microscopy (Nikon Eclipse TS100). 
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Figure 3-4. Embryoid body spontaneous differentiation of ESCs 
WT or different lines of mutant 30 kD ESCs (Cl 005, Cl 016, Cl 061, Cl 071, and Cl 098) 
were dissociated into hanging drops and transferred to ultralow attachment dishes in the 
absence of leukemia inhibitory factor (LIF). At day 4, embryoid body (EB) formation 
was observed and captured by inverted microscopy (Nikon Eclipse TS100). 
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OCT-4 (a pluripotent marker) positive epiblast cells. Overlay showed a nice ring, halo-
like structure. However, for the 30 kD mutant EBs, the OCT-4 positive cells were 
observed, but few DAB-2 positive cells located at the periphery, indicating a defect of 30 
kD ESCs to differentiate to extraembryonic endoderm, which is consistent with the 
trophectoderm defect during peri-implantation stage of Mcl-1-null embryos  
(Figure 3-5A). RNAs from WT and 30 kD mutant EBs were extracted at day 4 and 
quantitative real-time PCR (qPCR) was performed to assess the markers from each 
lineage. qPCR suggested a broader differentiation defects in 30 kD mutant EBs compared 
with WT, showing dramatic decreased levels of Sry-related high-mobility group box 7 
(SOX7), another extraembryonic endoderm marker, fibroblast growth factor 5 (FGF5), a 
ectoderm marker, paired related homeobox 1 (mHOX), a mesoderm marker, and Indian 
hedgehog (IHH), an endoderm marker (Figure 3-5B). These data, taken together, 
indicate that N-terminal truncated MCL-1 ESCs present as a sick phenotype and fail to 
differentiate to broad lineages, including extraembryonic endoderm, ectoderm, 
mesoderm, and endoderm. 
 
Teratoma formation assay is an in vivo assay to test the pluripotency of ESCs and 
their capability of differentiation. One million WT control ESCs or 30 kD mutant ESCs 
were injected into the flank of nude mice: two out of three WT ESCs gave rise to big 
teratomas 25 days post-implantation (Figure 3-6A). However, 30 kD ESCs failed to give 
rise to any size tumors at the same given time (Figure 3-6A). In order to test whether the 
effect is MCL-1 specific and not random off-target effect in one special ES clone, one 
million of the targeted pool ESCs were injected into the flank of nude mice. Three out of 
four low efficient CRISPR-targeted pool ESCs gave rise to teratomas 25 days post 
implantation, while only one out of four high efficient pool cells produced a tiny tumor 
when harvested at the same time (Figure 3-6A). Hematoxylin and eosin (H&E) stain of 
WT control teratoma showed tissues from all three germ lineages, surface ectoderm as 
the keratinized epithelial, neural ectoderm as neuronal rosettes, mesoderm such as 
cartilages as well as the striated muscles, and endoderm showing as the respiratory 
epithelial with mucus cells and cilia (Figure 3-6B). These data, consistent with the in 
vitro differentiation assay, suggested that N-terminal truncated mutants ESCs fail to 
differentiate to broad germ lineages in vivo. 
 
 
Mutant MCL-1 Is Capable of Antagonizing Cell Death and Localizes to the Outer 
Mitochondrial Membrane 
 
MCL-1 is well-known for its anti-apoptotic function, therefore it is important to 
test whether 30 kD mutant ESCs can antagonize cell death. Staurosporine, a broad kinase 
inhibitor capable of inducing apoptosis, was added at different doses on WT ESCs and 
different lines of 30 kD mutants. The curves representing the percentage of annexin 
positive cells at different doses of staurosporine didn’t show obvious differences among 
WT ESCs and several 30 kD ESC lines (Figure 3-7A). The subcellular localization data 
showed that WT MCL-1 and 30 kD mutant MCL-1 were enriched at the heavy membrane 
(HM), indicating their mitochondrial localization (Figure 3-7B). Further, proteinase K 
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Figure 3-5. 30 kD mutant ESCs show broad differentiation defects 
(A) Expression of DAB-2 and OCT-4 in the embryoid body day 10. Cryosections of 
spontaneous differentiation embryoid bodies (WT versus two lines of 30 kD) at day 10 
were immunostained with anti-DAB-2 and anti-OCT-4 antibodies. Sections were 
counterstained with the DNA dye DAPI. All images were captured by using a 
microscopy (Zeiss Axioskop II Plus). (B) Real-time PCR with fast SYBR green (Bio-
Rad) detection was performed by using QuantStudio 7 Flex (Life technologies). Primers 
used were Sox2 (pluripotency marker), Oct4 (pluripotency marker), Sox7 
(extraembryonic endoderm), Fgf5 (ectoderm), mHox (mesoderm), Ihh (endoderm). 
Double delta Ct analysis was used to calculate the mRNA levels. The assay was done in 
triplicate for each sample. Error bars represent the standard error of the mean.  
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Figure 3-6. 30 kD mutant ESCs fail to give rise to teratoma 
(A) Teratoma formation of WT, 30 kD ESCs and low versus high efficient CRISPR-Cas9 
targeted pool ESCs. One million ESCs were injected into the flank of each 
immunodeficient recipient and tumors were harvested 25 days post implantation. (B) 
H&E stain of WT teratomas showed tissues from all three germ layers, I (low 
magnification), II-VI (high magnification), II (surface ectoderm as the keratinized 
epithelial), III (neural ectoderm as neuronal rosettes), IV (mesoderm as cartilages), V 
(mesoderm as striated muscles), and VI (endoderm showing as the respiratory epithelial 
with mucus cells and cilia).  
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Figure 3-7. 30 kD mutant ESCs retain anti-apoptotic function and reside on the 
outer mitochondrial membrane 
(A) WT ESCs and different lines of 30 kD ESCs were administered indicated doses of 
staurosporine for 16 hours after which cell death assay by flow cytometry was 
determined. Bars represent the average of 3 independent experiments and the error bars 
denote the SEM. (B) Mitochondria enriched, heavy membrane (HM) or cytosol (S100) 
fractions were isolated from WT and 30 kD ESCs. Whole cell lysates (WCL) acted as a 
control. Fractions were resolved and immunoblotted for MCL-1. OPA-1, MnSOD, or 
BIM worked as intermitochondrial membrane, inner matrix or cytosolic marker, 
respectively. (C) Mitochondria isolated from WT or 30 kD ESCs were subjected to 
proteinase K (PK) proteolysis. Osmotic shock was used to disrupt outer mitochondrial 
membrane (OMM), and detergent SDS was used to disrupt both inner and outer 
mitochondrial membranes. Lysates were collected and subjected to immunoblot analyses.  
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assay was carried out on the isolated mitochondria. Upper and middle bands of MCL-1 
were both sensitive to proteinase K digestion, but the lower band was resistant even 
under the osmotic shock.  This is consistent with our previous finding suggesting that WT 
MCL-1 retains outer mitochondrial membrane and matrix dual localizations  
(Figure 3-7C). However, 30 kD mutant MCL-1 only has one band and was sensitive to 
proteinase K cleavage, indicating that it only resides on the outer mitochondrial 
membrane (Figure 3-7C).  
 
To further evaluate the anti-apoptotic function and the subcellular localization of 
30 kD mutant MCL-1, our inducible mouse embryonic fibroblasts (MEFs) were utilized. 
The second methionine 30 kD mutant MCL-1 was made by either mutating the first 
methionine to TGA stop code called ATG1, or by truncation of the N-terminal 91 amino 
acids named M92. MSCV-puro vector, WT MCL-1, ATG1 and M92 were overexpressed 
to Mcl-1flox/flox CREERT2 SV40 transformed MEFs and then selected by puromycin. After 
the stable cell lines were established, they were treated with tamoxifen for 48 hours.  
Immunoblotting showed the endogenous MCL-1 was completely deleted and WT MCL-1 
as well as ATG1, M92 mutant MCL-1 were well expressed (Figure 3-8A). Cell death 
assay by staurosporine at different doses was repeated. MCL-1-deleted MEFs 
overexpressing the empty vector were sensitive to death stimuli and dramatic cell death 
was achieved at relative lower staurosporine doses (Figure 3-8B).  MCL-1 deleted MEFs 
overexpressing either WT MCL-1, ATG1 or M92 exhibited resistance to cell death 
stimuli (Figure 3-8B).  One mechanism of MCL-1’s anti-apoptotic role is to bind with 
the pro-apoptotic death sensor BIM by using its hydrophobic groove to block BAX/BAK 
activation. Further, BIM immunoprecipitation (IP) experiment revealed that ATG1 and 
M92 were capable of binding to BIM like the upper anti-apoptotic MCL-1 species 
(Figure 3-8C). Consistent with the proteinase K assay in ESCs, in the inducible MEFs 
system WT MCL-1 retained its dual subcellular localization by presenting with both 
sensitive upper band and resistant lower band to proteinase K. In contrast, both ATG1 
and M92 exhibited one band which was sensitive to enzyme digestion, further suggesting 
its only outer mitochondrial membrane localization (Figure 3-8D).  
 
 
Establish Mcl-1flox/flox CREERT2 ESCs for Rescue Experiment 
 
To rescue the differentiation defect from mutant MCL-1, Mcl-1flox/flox CREERT2 
ESCs were derived as well as Mcl-1flox/WT CREERT2 and Mcl-1flox/flox controls. 
Immunoblotting data suggested endogenous MCL-1 was well deleted 48 hours after 
tamoxifen treatment on both Mcl-1flox/flox CREERT2 ESCs and embryoid bodies (EBs) day 
4 (Figure 3-9A). Mcl-1flox/WT CREERT2 treated with tamoxifen showed decreased level of 
MCL-1 compared with Mcl-1flox/WT CREERT2 vehicle treated (Figure 3-9A). When seeded 
equal number of cells in culture in the presence or absence of tamoxifen and followed for 
growth, tamoxifen treated Mcl-1flox/flox CREERT2 ESCs stopped expanding in culture while 
Mcl-1flox/flox CREERT2 ESCs untreated as well as Mcl-1flox/flox regardless of the presence of 
tamoxifen showed exponential growth curve (Figure 3-9B). Mcl-1flox/WT CREERT2 treated 
with tamoxifen exhibited slower growth rate compared with Mcl-1flox/WT CREERT2 in the  
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Figure 3-8. Generation of inducible MEFs overexpressing 30 kD mutant for cell 
death and subcellular localization analyses 
(A) Western blot of the Mcl-1flox/flox CREERT2 SV40 transformed MEFs stably 
overexpressing MSCV-puro vector, WT MCL-1, ATG1, and M92 treated with tamoxifen 
for 48 hours for anti-MCL-1. Anti-α-actin acted as a loading control. (B) Mcl-1flox/flox 
CREERT2 SV40 transformed MEFs stably overexpressing MSCV-puro vector, WT MCL-
1, ATG1, and M92 treated with tamoxifen for 48 hours were administered indicated 
doses of staurosporine for 16 hours after which cell death assay by flow cytometry was 
determined. Bars represent the average of 3 independent experiments and the error bars 
denote the SEM. (C) Whole cell lysates (WCLs) of Mcl-1flox/flox CREERT2 SV40 
transformed MEFs stably overexpressing MSCV-puro vector, WT MCL-1, ATG1, and 
M92 treated with tamoxifen for 48 hours were collected and coupled with anti-BIM rat 
monoclonal antibody, and then precipitated with protein A/G-plus agarose. 
Immunocomplexes and post-immnoprecipitated supernatants were subjected to 
immunoblotting for anti-MCL-1 and anti-BIM. (D) Mitochondria isolated from Mcl-
1flox/flox CREERT2 SV40 transformed MEFs stably overexpressing MSCV-puro vector, WT 
MCL-1, ATG1, and M92 treated with tamoxifen for 48 hours were subjected to 
proteinase K (PK) proteolysis. Osmotic shock was used to disrupt outer mitochondrial 
membrane (OMM), and detergent SDS was used to disrupt both inner and outer 
mitochondrial membranes. Lysates were collected and subjected to immunoblot analyses. 
OPA-1, MnSOD, or mouse BCL-2 worked as intermitochondrial membrane, inner matrix 
or cytosolic marker, respectively. 
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Figure 3-9. Mcl-1-deleted Mcl-1flox/flox CREERT2 ESCs fail to proliferate in vitro 
and give rise to teratoma in vivo 
(A) Western blot of the Mcl-1flox/flox CREERT2, Mcl-1flox/flox, and Mcl-1flox/WT CREERT2 
ESCs in the absence and presence of tamoxifen for 48 hours. Anti-α-actin acted as a 
loading control. (B) Mcl-1flox/flox CREERT2, Mcl-1flox/flox, and Mcl-1flox/WT CREERT2 ESCs in 
the absence and presence of tamoxifen were seeded equal number of cells in culture and 
followed and plotted for growth curves. Bars represent the average of 3 independent 
experiments and the error bars denote the SEM. #p>0.05 and **p<0.01 as determined by 
two-tailed Student t test. (C) Teratoma formation of Mcl-1flox/flox CREERT2, Mcl-1flox/flox, 
and Mcl-1flox/WT CREERT2 ESCs in the absence and presence of tamoxifen. One million of 
each ESCs were injected into the flank of immunodeficient recipient and tumors were 
palpated every the other day. Mcl-1flox/flox and Mcl-1flox/WT CREERT2 teratomas regardless 
of tamoxifen treatment were harvested 25 days post implantation, while Mcl-1flox/flox 
CREERT2 teratomas were harvested 39 days post implantation.  
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absence of tamoxifen (Figure 3-9B). To test whether the Mcl-1flox/flox CREERT2 ESCs we 
generated retained pluripotency and response to tamoxifen in vivo, one million of ESCs 
were injected into the flank of nude mice and vehicle or tamoxifen gavage was performed 
one week post the implantation, five days in a row. All four immunodeficient recipients 
receiving Mcl-1flox/flox CREERT2 ESCs treated with vehicle had teratomas at 39 days after 
implantation. However, none of the recipients transplanted with Mcl-1flox/flox CREERT2 and 
treated with tamoxifen had observable tumors at the same time (Figure 3-9C).  Mcl-
1flox/WT CREERT2 and Mcl-1flox/flox ESCs treated either with vehicle or tamoxifen gave rise 
to big size teratomas at 25 days after injection (Figure 3-9C). These data taken together 
suggest that MCL-1 is required for ESCs proliferation and differentiation to multiple 
germ lineages.  ESCs with one deleted allele of MCL-1 showed attenuated growth rate in 
culture.  
 
 We further made mutants to dissect MCL-1’s two isoforms for ESCs rescue 
purpose. CS10, 11 and CS33, 34 MCL-1 were generated by either mutagenesis of amino acids 
at position 10, 11 from isoleucine, glycine to aspartic acid, aspartic acid or amino acids at 
position 33, 34 from leucine, valine to aspartic acid, aspartic acid (Figure 3-10A). To 
generate a MCL-1 mutant that only restricts within matrix, we fused the mitochondrial 
targeting sequence from ATP synthase to N-terminal 34 amino acids truncated MCL-1, 
call Matrix MCL-1 (Figure 3-10A). Consistent with our hypothesis, compared with WT 
MCL-1’s dual localization, Matrix MCL-1 only formed one band which was completely 
resistant to enzyme digestion even under the osmotic shock, suggesting its mitochondrial 
matrix only localization (Figure 3-10B). Both CS10, 11 and CS33, 34 MCL-1 were sensitive 
to proteinase K, therefore they only reside on the outer mitochondrial membrane  
(Figure 3-10B). And our previous functional studies indicated that two species of MCL-1 
retain different functions due to their distinct localization. Outer mitochondrial membrane 
localized MCL-1 performs the classical anti-apoptotic function by antagonizing BAX and 
BAK, while matrix localized MCL-1 does not possess anti-apoptotic activity, but plays a 
role in maintaining mitochondrial ultrastructure, promoting mitochondrial fusion and 
fission, supporting the assembly of ATP synthase oligomers and oxidative 
phosphorylation [38].  
 
 To evaluate which MCL-1 function would rescue the defects of ESCs, MSCV-I-
GFP (MIG) Vector, WT MCL-1, CS10,11, Matrix, 30 kD MCL-1 or hBCL-2 was 
overexpressed onto Mcl-1flox/flox CREERT2 ESCs by viral transduction. Tamoxifen or 
vehicle was performed on each of them and cell lysates were harvested at either day 3 
and 6 to check the endogenous MCL-1 deletion efficiency as well as the exogenous 
overexpression level. The Mcl-1flox/flox CREERT2 ESCs overexpressing MIG vector 
showed good deletion efficiency on day 3 after tamoxifen treatment, however at day 6, 
the endogenous MCL-1 could not be deleted in the presence of tamoxifen, indicating a 
long-term selection pressure against MCL-1 loss (Figure 3-11A). This finding is 
consistent with our previous publication that there was strong selection against MCL-1 
loss during BCL-ABL pre-B leukemia transformation in vitro and in vivo [110]. WT, 
CS10, 11, Matrix, 30 kD MCL-1 and hBCL-2 were well-expressed and the endogenous 
MCL-1 in these groups were well-deleted (Figure 3-11A). When seeded equal number of 
cells in the presence or absence of tamoxifen in culture, Mcl-1flox/flox CREERT2 ESCs  
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Figure 3-10. Dissect MCL-1’s two isoforms for rescue experiments 
(A) Schematic illustration of cleavage sites mutants and Matrix mutant of MCL-1. CS10, 
11 and CS33, 34 MCL-1 were generated by either mutagenesis of amino acids at position 10, 
11 from isoleucine, glycine to aspartic acid, aspartic acid or amino acids at position 33, 
34 from leucine, valine to aspartic acid, aspartic acid. Matrix MCL-1 was generated by 
fusing the mitochondrial targeting sequence from ATP synthase to N-terminal 34 amino 
acids truncated MCL-1. (B) Mitochondria isolated from Mcl-1-deleted Mcl-1flox/flox 
CREERT2 SV40 transformed MEFs stably overexpressing MSCV-puro WT MCL-1, CS10, 
11, CS33, 34 , Matrix MCL-1 treated with tamoxifen for 48 hours were subjected to 
proteinase K (PK) proteolysis. Osmotic shock was used to disrupt outer mitochondrial 
membrane (OMM), and detergent SDS was used to disrupt both inner and outer 
mitochondrial membranes. Lysates were collected and subjected to immunoblot analyses. 
OPA-1, MnSOD, or mouse BCL-2 worked as intermitochondrial membrane, inner matrix 
or cytosolic marker, respectively. 
  
 44 
 
 
Figure 3-11. Put back MCL-1 mutants for proliferation rescue 
(A) Western blot of Mcl-1flox/flox CREERT2 ESCs overexpressing MIG Vector with or 
without tamoxifen, WT MCL-1, CS10, 11, Matrix, 30 kD MCL-1, and hBCL2 with 
tamoxifen for either 3 days or 6 days. (B) Mcl-1flox/flox CREERT2 ESCs overexpressing 
MIG Vector with or without tamoxifen, WT MCL-1, CS10, 11, Matrix, 30 kD MCL-1, and 
hBCL2 with tamoxifen were seeded equal number of cells and growth curves were 
plotted. Bars represent the average of 3 independent experiments and the error bars 
denote the SEM. #p>0.05, *p<0.05, and **p<0.01 as determined by two-tailed Student t 
test when compared to Mcl-1flox/flox CREERT2 ESCs overexpressing Vector treated with 
tamoxifen. 
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overexpressing MIG vector in the absence of tamoxifen showed exponential growth, 
while the same cells treated with tamoxifen failed to proliferate (Figure 3-11B). All 
mutants with anti-apoptotic function, WT, CS10, 11, 30 kD MCL-1 and hBCL-2, rescued 
the growth of the Mcl-1-deleted MIG vector overexpressing ESCs. Matrix MCL-1, 
without anti-apoptotic activity, failed to rescue the proliferation (Figure 3-11B). These 
data, taken together, suggest that anti-apoptotic function of MCL-1 is required for ESCs 
survival and proliferation.  
 
 To examine whether different MCL-1 species can rescue the differentiation 
defect, one million of each ESCs were injected into the flank of nude mice and either 
tamoxifen or vehicle was performed one week after implantation, five days in a row. Mcl-
1flox/flox CREERT2 ESCs overexpressing MIG vector treated with vehicle gave rise to big 
size teratomas 35 days after the injection (row 1), while the same cells treated with 
tamoxifen failed to generate any tumors during the same period (not shown)  
(Figure 3-12A). All three immunodeficient recipients receiving tamoxifen treated Mcl-
1flox/flox CREERT2 ESCs overexpressing MIG WT MCL-1 had big size teratomas (row 2), 
however, adding back the 30 kD MCL-1 mutant failed to give rise to any size teratomas 
within the same time frame (data not shown) (Figure 3-12A). Mcl-1flox/flox CREERT2 ESCs 
overexpressing anti-apoptotic only mutant CS10, 11 MCL-1 or hBCL2 treated with 
tamoxifen generated smaller teratomas with pale color (rows 3 and 5).   When the Matrix 
form was added back only one out of three gave rise to pale teratoma 35 days after 
implantation (row 4) (Figure 3-12A). According to histology review, teratomas from all 
recipients receiving Mcl-1flox/flox CREERT2 ESCs overexpressing the MIG vector treated 
with vehicle and overexpressing the WT MCL-1 treated with tamoxifen had all three 
germ layers, including neuroectoderm tissues, surface ectoderm epidermal elements, 
endoderm tissues like ciliated respiratory epithelium and mesoderm tissues such as 
striated muscles as well as cartilages. However, teratomas harvested from recipients 
transplanted with Mcl-1flox/flox CREERT2 ESCs overexpressing the anti-apoptotic only 
mutant CS10, 11 of MCL-1 treated with tamoxifen failed to give rise to distinct three germ 
layer tissues, but contained foci suggestive of vast amount of primitive undifferentiated 
tissues. PCR for deleted alleles from teratomas showed distinct deletion bands in all 
samples treated with tamoxifen (Figure 3-12B). And further immunoblotting from 
teratoma samples exhibited good deletion efficiency and overexpression levels except 
that one teratoma sample harvested from the recipient receiving tamoxifen treated Mcl-
1flox/flox CREERT2 ESCs overexpressing Matrix showed observable endogenous MCL-1 
bands (Figure 3-12C). These data, taken together, indicate that exogenous WT MCL-1 
can rescue both the proliferation and differentiation of Mcl-1-deleted ESCs, however, 
anti-apoptotic only mutants, CS10, 11, 30 kD MCL-1 and hBCL-2, could only rescue 
proliferation. Neither anti-apoptotic only mutants nor Matrix species of MCL-1 were able 
to fully rescue the differentiation in the Mcl-1-deficient ESCs.  
 
 
Zygote Injection to Generate MCL-1 Mutant Mice 
 
 To study MCL-1 mutants (CS10, 11 and 30 kD MCL-1) in a more physiological 
setting, we performed zygote injection to generate mutants knock-in mice.  
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Figure 3-12. Teratoma formation needs both forms of MCL-1 
(A) One million Mcl-1flox/flox CREERT2 ESCs overexpressing either MIG Vector, WT 
MCL-1, CS10, 11, Matrix, 30 kD MCL-1, or hBCL2 ESCs were injected into the flank of 
immunodeficient recipient and tamoxifen gavage was performed one week after the 
implantation, five days in a row. Tumors were palpated every the other day and all the 
tumors were harvested 35 days post implantation. (B) DNA was extracted from each 
teratoma lysate and PCR was performed for the deleted allele. (C) Immunoblots from 
each teratoma lysates to show endogenous MCL-1 deletion as well as the exogenous 
mutant overexpression.    
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In vitro transcribed Cas9 mRNA, guide RNA (F3 or R2), and guide RNA related ssODN 
were injected into mouse zygotes. The ssODNs consisted of either symmetric or 
asymmetric homologous arms, Mcl-1 amino acid 10, 11 mutagenesis, and silent mutation 
of CRISPR recognition sites in order to prevent recurrent targeting. The asymmetric 
repair template design has been suggested to increase the homologous recombination 
efficiency [111]. According to the deep sequencing result of 19 founders’ toe DNAs from 
zygote injection, 11 of them had mutations, with either deletion (red bar), insertion (green 
bar) or replacement mutation (orange color). The total mutation efficiency in founders 
was 58% and 31.5%, 10.5% and 16% for deletion, insertion and replacement mutation, 
respectively (Figure 3-13). Two founders, xy007 and xy009, obtained the desired 
mutagenesis encoding amino acids 10, 11 aspartic acid, aspartic acid to replace the 
original wild-type isoleucine, glycine with mutation percentages 3.34% and 14.99%, 
respectively. Interestingly, xy012 founder carried a desired CS10, 11 mutation followed by 
an in-frame stop codon TAG, which presumably would generate 30 kD KI mice with a 
mutated allele frequency of 21.88% (Figure 3-13). Since Cas9 is active as the zygotes 
divide, the founders are expected to be germline mosaic and the percentages roughly 
represent the mutated allele frequencies (Figure 3-13). We bred the desired CS10,11 KI 
founders xy007 and xy009 as well as the KI plus stop codon mouse, presumably 30 kD 
KI founder, in the same mouse background C57BL/6J to generate KI F1 generation.  
 
Genomic DNAs extracted from tails of KI F1 pups were amplified and subjected 
to Taq I enzyme digestion (Figure 3-14A) and Sanger sequencing (Figure 3-14B). CS10, 
11 mutagenesis creates a unique Taq I enzyme site, therefore, KI alleles could be detected 
by Taq I cleavage. Compared with uncut, full-length amplicon plus cleavage bands 
suggested KI heterozygous in the presence of Taq I (Figure 3-14A). Wild-type from 
Sanger sequencing were determined by comparison to mouse Mcl-1 genomic sequences 
and heterozygous mutations were determined by filtering out the known sequence of the 
WT allele (Figure 3-14B). CS10, 11 KI F1 pups (WT/ CS10, 11 heterozygous) were 
successfully obtained from xy009 founders but not xy007.  The reason could be that the 
mutated allele frequency in xy007 was too low to get germline transmission. CS10, 11 KI 
followed by an in-frame stop codon F1 pups (WT/ CS10, 11 TAG) were also derived. To 
dilute out potential off-target effects from CRISPR-Cas9, derived heterozygous F1 CS10, 
11 KI and CS10, 11 TAG were bred back to WT C57BL/6J mice for at least 3 generations. 
One-time CS10, 11 KI F1 heterozygous crossbreed generated seven pups. Genomic DNAs 
collected from neonatal tails were amplified and treated by Taq I enzyme digestion and 
cleavage bands only in the presence of Taq I suggested homozygous KI pups  
(Figure 3-14C). Homozygous mutations were further validated by Sanger sequencing 
and compared to mouse Mcl-1 genomic sequences (Figure 3-14D).  
 
Immunoblotting of neonatal tail fibroblast cells from the seven pups generated by 
CS10, 11 KI F1 heterozygous mice showed no obvious lower band (Matrix isoform) of 
MCL-1 in Taq I and Sanger sequencing validated CS10, 11 KI homozygous (#1 and #7). 
Heterozygous (#2, #4, #5, and #6) exhibited decreased lower bands of MCL-1 compared 
with WT littermate (#3) (Figure 3-15A). Subcellular localization suggested CS10, 11   
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Figure 3-13. Deep sequencing shows mutations and mutation efficiencies in 
founders after zygote injection 
(A) DNA was extracted from the toe of each founder mouse generated from zygote 
injection. Amplicons from different samples were pooled together and barcoded by 
another round of PCR by using a Nextera Index Kit. The library prepared from the final 
PCR products of indexed samples was subjected to a 300bp-paired-end sequencing with 
Illumina Miseq for the targeted region. Red, green, and orange bars suggest deletion, 
insertion, and replacement mutation, respectively. Percentages represent the mutated 
allele frequencies.  
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Figure 3-14. Derivation of CS10, 11 and 30 kD KI mice 
(A) DNAs extracted from tails of KI F1 pups were amplified and subjected to Taq I 
enzyme digestion. (B) DNAs extracted from tails of KI F1 pups were amplified and sent 
for Sanger sequencing. (C) Genomic DNAs were extracted from the toes of the pups 
derived from CS10, 11 KI F1 heterozygous crossbreeding. Then, DNA collected were 
amplified and treated by Taq I enzyme digestion. (D) Amplicons collected were sent for 
Sanger sequencing for further validation. 
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Figure 3-15. Validation of CS10, 11 and 30 kD KI mice 
(A) Western blot of the neonatal tail fibroblast cells from the WT, CS10, 11 KI 
homozygous and CS10, 11 heterozygous validated from both Taq I and Sanger sequencing. 
#1 and #7 are CS10, 11 KI homozygous, #2, #4, #5, and #6 are heterozygous, and #3 is WT 
littermate. (B) Mitochondria enriched, heavy membrane (HM) or cytosol (S100) fractions 
were isolated from CS10, 11 KI homozygous, heterozygous, and WT neonatal tail 
fibroblast cells. Whole cell lysates (WCL) acted as a control. Fractions were resolved and 
immunoblotted for MCL-1. OPA-1, BCL-2 or BAX worked as intermitochondrial 
membrane, outer membrane or cytosolic marker, respectively. (C) Mitochondria isolated 
from CS10, 11 KI homozygous, heterozygous, and WT neonatal tail fibroblast cells were 
subjected to proteinase K (PK) proteolysis. Osmotic shock was used to disrupt outer 
mitochondrial membrane (OMM), and detergent SDS was used to disrupt both inner and 
outer mitochondrial membranes. Lysates were collected and subjected to immunoblot 
analyses for MCL-1, OPA-1 (intermembrane marker), BCL-2 (outer membrane marker), 
and ATP5B (matrix marker). 
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MCL-1 enriched in the heavy membrane (HM) as WT MCL-1 (Figure 3-15B). Further 
proteinase K assay indicated that WT MCL-1 retained dual localization as shown by 
proteinase K sensitive upper band and resistant lower band (Figure 3-15C). CS10, 11 KI 
MCL-1 only exhibited one band and was completely sensitive to enzyme digestion, 
suggesting its outer mitochondrial only localization (Figure 3-15C).  
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CHAPTER 4.    DISCUSSION 
 
 
MCL-1 in Normal Biology 
 
 Gene-ablation study uncovered a non-redundant and distinct role of MCL-1 as a 
BCL-2 family member. Deletion of Mcl-1 resulted in embryonic lethality due to peri-
implantation failure on E3.5 [16], however, genetic deletion of other anti-apoptotic BCL-
2 family members do not result in such severe phenotype [11-14]. Induced deletion of 
Mcl-1 during different stages of hematopoiesis and different lineages indicates that MCL-
1 is essential for the survival and differentiation for multiple hematopoietic lineages, 
including pre-B and progenitor T cells, HSCs, CMPs, CLPs, as well as mature 
neutrophils, plasma cells, red blood cells, and NK cells, etc. [17-23]. In contrast, other 
pro-survival family members play much more selective roles in hematopoiesis [11, 14, 
24, 25]. Additionally, cardiac-specific ablation of Mcl-1 also leads to a dilated 
cardiomyopathy and rapidly fatal phenotype [26, 27]. However, all previous gene 
ablation studies disable both classical anti-apoptotic activity on the outer mitochondrial 
membrane and mitochondrial function species in the mitochondria matrix. Therefore, to 
determine the relative contribution of MCL-1’s different functional roles for supporting 
the survival and differentiation of various cellular lineages, it is important to dissect the 
two species. It is proposed that both species may be critical for normal cell biology, 
including supporting survival, promoting proliferation and differentiation, as well as 
regulating the homeostasis response to growth factors or cellular signals. However, these 
two species may contribute differently during developmental stages or on distinct cell 
types. For example, hematopoietic cells are highly proliferative and more vulnerable to 
cellular stress, therefore, they are extremely dependent on anti-apoptotic MCL-1 for 
survival. Another example are pluripotent stem cells which remain relatively metabolic 
inactive by utilizing anaerobic glycolysis. When differentiating into their progenies, 
metabolic demands from a major glycolysis to oxidative phosphorylation switch of those 
pluripotent stem cells may require mitochondrial function of MCL-1.  
 
 
MCL-1 in Embryonic Development 
 
 The study that germline ablation of Mcl-1 in mice resulted in an early peri-
implantation failure at E3.5 highlights a non-redundant and distinct role of MCL-1 
among BCL-2 family members [16]. Other pro-survival members do not have such an 
early developmental defect, suggesting that MCL-1 may have a unique function during 
this early embryonic developmental stage. In the Mcl-1 germline ablation study, the 
authors found deletion of Mcl-1 resulted in early embryonic lethality, however, they 
claimed the defect was a trophectoderm (TE) defect rather than the inner cell mass (ICM) 
apoptosis.  This was demonstrated by the evidences that Mcl-1-null blastocysts failed to 
attach in vitro and Mcl-1 null blastocysts show no signs of increased apoptosis, but a 
delay in maturation beyond the pre-compaction stage, further indicating a role of MCL-1 
beyond anti-apoptosis during early embryonic stage [16].  
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 In our study, we designed nine guide RNAs to target Mcl-1’s start codon and total 
mutation efficiencies range from 75%-96%. Unlike SV40-transformed MEFs which can 
tolerate MCL-1 loss, disruption of Mcl-1’s first methionine in ESCs all generated a 30 kD 
short truncated protein of MCL-1 maintaining its anti-apoptotic core, suggesting that 
MCL-1’s anti-apoptotic function is essential for ESC survival. Although 30 kD MCL-1 
maintained classical anti-apoptotic function, mutant ESCs presented sick phenotypes and 
failed to differentiate to extraembryonic endoderm, which is consistent with the 
trophectoderm defect from genetic ablation of Mcl-1. Further q-PCR results even 
suggested broad differentiation defects, including ectoderm, mesoderm, and endoderm 
layers. Rescue experiment by putting back different MCL-1 mutant showed only WT 
MCL-1 can fully rescue the differentiation defect of teratoma formation, neither anti-
apoptotic 30 kD, CS10, 11 MCL-1 nor mitochondria matrix species completely rescue the 
defect. These data, taken together, suggest that in addition to MCL-1’s required 
antagonism of cell death by the C-terminal region, MCL-1’s N-terminus is required for 
efficient cellular differentiation, potentially by facilitating MCL-1’s import into the 
mitochondrial matrix. However, the mechanistic underpinnings of the anti-apoptotic 
function and mitochondrial promoting activity in determining ESC differentiation 
remains to be elucidated.  
 
 
 Metabolic Requirements during Embryogenesis.  Mitochondria of the oocyte 
and early embryo are known to be small with few cristae and less electron transport 
chains, but those mitochondria are highly active in oxidative phosphorylation to generate 
ATP in support of the metabolic demands of early development [112-114]. And it is well-
known that mitochondrial replication of the oocyte is arrested in metaphase II of meiosis 
and is only reactivated upon implantation into the uterine wall [115]. Post-fertilization, 
mitochondria undergo dramatic maturation into the elongated “spaghetti-like” and 
cristae-rich structures and failure to acquire this mature mitochondrial ultrastructure 
results in arrested embryos [116-118]. Further following implantation, a transition from 
glycolysis to oxidative phosphorylation is essential for successful early embryogenesis, 
as shown by a developmental delay or late onset lethality with mutations that impair 
oxidative metabolism [119, 120]. MCL-1 is required for early implantation, however the 
mechanism has still remained elusive. It is possible that MCL-1 facilitates mitochondrial 
ultrastructure and provides sufficient energy production that is required for the 
trophectoderm to implant. Another possibility is that MCL-1 promotes mitochondrial 
physiology and oxidative phosphorylation to prime the differentiation of cytotrophoblast 
cells, failure of which results in a defective trophectoderm to implant. Therefore, it is 
conceivable that other than MCL-1’s required antagonism of cell death, MCL-1’s role to 
maintain normal mitochondrial physiology and promote differentiation is also important 
during early embryonic development. 
 
 
 Metabolic Determinants of Embryonic Stem Cell Fate.  Embryonic stem cells 
are derived from the inner cell mass of the pre-implantation blastocyst around E3.5 and 
represent the gold-standard of “stemness”, which means they obtain pluripotency, 
capable of differentiating into broad tissue-specific lineages, and self-renewal, the ability 
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to self-replicate maintaining the undifferentiated pool.  Similar to their tissue origin, 
embryonic stem cells are characterized by a low mtDNA content and immature 
mitochondrial ultrastructure with poorly developed cristae, which is also a universal 
feature across a variety of stem cell populations, including hematopoietic stem cells 
(HSCs) and mesenchymal stem cells (MSCs) [121-123]. It is now well-accepted that 
glycolysis fuels not only energy (ATP) but also building blocks (carbon, nitrogen, and 
hydrogen) for stem cell proliferation and self-renewal [124, 125]. Stimulating glycolysis 
in pluripotent stem cells through hypoxia or suppressing mitochondrial respiration 
promotes “stemness” while inhibition of glycolysis halts proliferation and accelerates cell 
death [126-128].  
 
 Pluripotent stem cells and their progenies have very different energetic 
requirement. Differentiated cells no longer sustain high proliferation rate, but rather 
perform specific specialized functions, such as rhythmic contraction in cardiomyocytes or 
electrical impulses in neurons, therefore, they demand large amount of energy to fuel 
those processes rather than anabolic synthesis for rapid proliferation [129]. When induced 
to differentiate, specific energetic and metabolic capacities are required to overcome 
barriers of the state conversion, evidenced by the downregulation of glycolysis and 
stemness genes while stimulation of mtDNA replication, mitochondrial biogenesis, 
maturation of extensive, interconnected networks of elongated and cristae-rich 
mitochondria as well as upregulation of TCA cycle players and electron transport chain 
components [123, 130-132]. Thus, a metabolic switch from glycolysis to mitochondrial 
oxidative phosphorylation is essential for stem cell differentiation; however, the 
mechanism of a causal role in cell fate determination remain to be unknown.  
 
Several studies have emphasized that mitochondrial regulation of reactive oxygen 
species (ROS) as well as stem cell differentiation inducers and antioxidants, impair the 
differentiation capability of HSCs and MSCs [132-135]. Other researchers report that 
several signaling pathways have been involved in regulating the metabolic switch. It is 
well-recognized that Smad1 and STAT3 act as key components to support stemness of 
pluripotent stem cells through signaling pathways mediated by bone morphogenetic 
protein (BMP) and leukemia inhibitory factor (LIF), respectively [136, 137]. PI3K-
mTOR pathway has also been revealed by several studies to regulate stemness of HSCs 
and tuberous sclerosis complex 1 (TSC1) activity, an upstream negative regulator of 
mTOR, is required to support HSC stemness by repressing mitochondrial biogenesis and 
ROS production [138-140]. Other than the metabolic regulation, cellular signaling, 
epigenetic control of transcription programs has also been reported to determine the stem 
cell fate. One example is that Moussaieff et al. showed that glycolysis-derived acetyl-
CoA prevents histone deacetylation and blocks differentiation of ESCs [141].  
 
In our work, we showed that N-terminal truncated mutant of MCL-1 ESCs failed 
to differentiate to broad germ lineages, including extraembryonic endoderm, ectoderm, 
mesoderm, and endoderm. N-terminal sequences of MCL-1 contain mitochondria 
targeting sequences, deletion of which abrogates MCL-1’s importation into the 
mitochondrial matrix. Matrix localized MCL-1 has been suggested to support 
mitochondrial ultrastructure, promote mitochondrial fusion and fission, and facilitate the 
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assembly of ATP synthase oligomers and oxidative phosphorylation [38]. It is possible 
that in the absence of matrix species of MCL-1, ESCs cannot make the switch from 
glycolysis to oxidative phosphorylation, and therefore, fail to overcome the energetic and 
metabolic barriers to undergo differentiation. Another possibility is that the N-terminus of 
MCL-1 is required for binding to certain key factors to activate differentiation pathways 
or inhibit signaling that maintain pluripotency. It is suggested that MCL-1 interacts with 
STAT3 at the window of implantation to promote the mesenchymal to epithelial 
transition (MET) required for successful implantation [142, 143].  
 
 
MCL-1 in Cardiac Homeostasis  
 
 
 Mitochondrial Function in Cardiomyocyte Development.  The development of 
the heart starts around E7.5, beating heart tube may be observed at E8.5, and the primary 
four cardiac chambers are formed around E10.5 [144]. Cardiomyocyte development has 
also been suggested to be dependent on mitochondrial status as cardiomyocytes from 
early embryos around E9.5 which show sparse fragmented mitochondria with poorly 
formed cristae and immature ultrastructure. Those immature mitochondria undergo 
extensive maturation into elongated and branched mitochondria with abundant and 
organized cristae by E13.5 [133]. Studies have shown that early induction of 
mitochondrial maturation accelerates cardiomyocyte differentiation, while forced arrest 
in the immature status of mitochondria impairs the differentiation of cardiomyocytes 
[133, 145]. MCL-1 is essential for cardiac development as evidenced by our previous 
study that induced deletion of Mcl-1 in heart by Ckmm-CRE at E13.5 leads to a fatal 
dilated cardiomyopathy [26].  
 
 
 MCL-1’s Dual Functions in Heart Homeostasis.  Cardiomyocytes are 
permanent cells and they lose their regenerative ability after postnatal day 7; therefore, 
they can only be repaired by connective tissues through fibrosis [146]. Deletion of Mcl-1 
in adult mice heart by tamoxifen inducible Myh-CREER also results in a rapid, fatal 
cardiomyopathy.  However, low but significant levels of apoptosis was observed, which 
is consistent with previous studies showing that even low levels of cell death are 
sufficient to cause cardiomyopathy because they lack of regeneration capability [26, 
147]. Further genetic ablation of pro-apoptotic Bax and Bak rescue the survival of 
cardiac-specific Mcl-1 deletion and improves cardiac function, indicating that MCL-1 
prevents heart failure and overt cardiomyopathy by blocking cell death [26]. Although 
deletion of Bax and Bak rescues loss of Mcl-1 and those mice did not display significant 
cardiac dysfunction, further analyses of the hearts from those mice reveal the 
heterogeneous myocardial organization with rounded and disorganized mitochondria.  
Respiratory defect as well as decreased mtDNA levels could not be rescued by Bax and 
Bak deficiencies [26].  Additionally, cardiac-specific Mcl-1 deletion in the absence of 
Bax and Bak shows cardiac dilation and contractile dysfunction under the isoproterenol 
challenge [26]. Taken together, these data suggest that both anti-apoptotic species and 
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mitochondria matrix species are necessary for heart homeostasis by promoting 
cardiomyocytes survival and facilitating mitochondrial physiology, respectively.  
 
 
MCL-1 in Hematopoiesis 
 
 Previous specific genetic ablation studies during different stages of hematopoiesis 
revealed that MCL-1 is unique and required for development and maintenance of 
hematopoiesis [17-23]. Deletion of MCL-1 in early hematopoietic progenitors, HSCs, 
double-negative T cells and pro-B stages, leads to an increased apoptosis and arrested 
development [17, 19]. In contrast, other pro-survival BCL-2 family members seem to 
play much more selective roles limited to more mature cells. Genetic ablation of BCL-2 
and BCL-XL leads to defects of mature lymphocytes and red blood cells, respectively [11, 
24]. A1 isoforms play a role, but are not indispensable for granulocyte and lymphoid 
development [14, 25]. Similar to embryonic stem cells discussed earlier, an energetic and 
metabolic reprogramming from glycolysis to oxidative phosphorylation is a universal 
feature across a variety of stem cell populations and is also essential for hematopoietic 
lineage specification [121]. Therefore, it is possible that both the Matrix and anti-
apoptotic MCL-1 forms are required to provide metabolic demands for hematopoietic 
lineage differentiation and to antagonize cell death to sustain maintenance of progenitor 
pool, respectively.  
 
 More committed lineages, such as mature lymphocytes or myelocytes, have 
different metabolic demands and no longer sustain high proliferation rate as their 
progenitors, but rather perform immune surveillance or phagocytosis under the regulation 
of cytokines and growth factors [6, 148]. Deletion of MCL-1 in mature hematopoietic 
lineages, such as mature neutrophils, plasma cells, red blood cells, and NK cells, have 
also been reported to cause dramatic increased apoptosis, indicating that more committed 
lineages are highly regulated by apoptosis [18, 20-23]. It is conceivable that matrix 
localized MCL-1 may be important for early progenitors as it facilitates the mitochondrial 
physiology to prime stem cells for differentiation, while anti-apoptotic MCL-1 may be 
more important for survival of the mature cells. Further studies are needed to separate 
these two functions of MCL-1 in order to understand their individual contributions to 
hematopoietic homeostasis.     
 
 
MCL-1 in Cancer Biology and Cancer Therapy 
 
 MCL-1 has been reported to be overexpressed in many human cancers, including 
acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic 
lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), neuroblastoma, 
melanoma, breast cancer, lung cancer [31]. The rationale for cancer cells displaying high 
level of MCL-1 is that those cancer cells often violate important cellular checkpoints 
which can drive the cells to die through apoptosis. Therefore, cancer cells need strategies 
for survival under the increased apoptotic stress by either downregulating pro-apoptotic 
regulators or, more frequently, upregulating pro-survival members like MCL-1 [36]. 
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More importantly, elevated level of MCL-1 expression often correlates with disease 
progression, chemotherapeutic resistance and relapse, highlighting the importance of 
understanding MCL-1’s contributions and regulations [32-35].   
 
 
Targeting MCL-1 as an Anti-apoptotic Protein 
 
 Since cancer cells are so “addicted” to anti-apoptotic BCL-2 family members as 
we discussed earlier, researchers have been working on developing small molecules to 
antagonize those pro-survival members. ABT-737/263, navitoclax, binds specifically 
with high affinity to pro-survival proteins BCL-2, BCL-xL, and BCL-w, but not to MCL-
1 and has been reported to induce regression of many solid tumors [94-96]. Though 
ABT-737 shows promising killing effect in certain tumors, its efficacy as a single agent is 
limited because of MCL-1 overexpression, which also represents a potential mechanism 
of resistance [149, 150]. Furthermore, the dose-limiting severe thrombocytopenia from 
navitoclax also quenched the enthusiasm for further clinical development of this 
compound [151]. ABT-199, venetoclax, has been developed and shown to have sub-
nanomolar affinity to BCL-2 with good anti-tumor activity sparing platelets on 
preclinical studies of many leukemia and lymphomas [152-155]. Most recent clinical 
trials have identified ABT-199 as a very effective drug either as a single agent or 
combined with traditional chemotherapy drug on CLL, even in relapsed or refractory 
patients, non-Hodgkin lymphoma, especially mantle cell lymphoma [156-158].  
 
 In 2016, Kotschy et al. developed a small molecule S63845 that specifically binds 
to the BH3-binding groove of MCL-1 with high affinity and showed very potent anti-
tumor activity with an acceptable safety margin either alone or in combination with other 
traditional chemotherapy drugs in treating a variety of tumors, such as multiple 
myelomas, leukemia, lymphoma cells and some other solid tumors [37]. The authors 
showed that S63845 kills tumor cells in a pro-apoptotic BAX/BAK dependent manner, 
which highlights MCL-1’s anti-apoptotic function as a target in cancer therapeutics [37]. 
This study provides preclinical evidence that MCL-1 is a promising target.  Inhibition of 
MCL-1 with S63845 is efficacious and tolerable, which may be explained by the 
overexpression of MCL-1 in tumor cells, making them more vulnerable than normal 
cells. Further studies are warranted to explore the potential of S63845 for the treatment of 
human cancers.  
 
 
Targeting Matrix-MCL-1 for Cancer Therapy 
 
 The function of MCL-1 in facilitating mitochondrial physiology offers another 
clue for targeting MCL-1 in cancer therapeutics. In contrast to conventional opinions, 
although mutations affecting mitochondrial functions are common in cancer cells, they do 
not disrupt the energetic and metabolic functions but rather reprogram the mitochondrial 
bioenergetics and biosynthetic status to meet the demands of cancer cells [43]. Functional 
mitochondria are essential for cancer cell survival, and cancer therapies targeting 
mitochondria have already been shown to be promising for cancer treatment [75]. 
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 Over the past decade, it has been demonstrated that for various malignancies, 
including leukemia and various solid tumors, cancer cells are heterogeneous and 
functionally inequivalent. Studies have shown that despite identical genetic background, 
there are a subset of cancer cells that acquire “stemness” features and have the ability to 
self-renew and give rise to heterogeneous cancer population. Thus, such cancer cells have 
been termed cancer stem cells (CSCs) or tumor-initiating cells (TICs) [159-161].  Similar 
to the normal stem cells, CSCs have also been shown to adopt primarily aerobic 
glycolysis over OXPHOS to maintain their “stemness” as well as proliferate [162-164]. 
The role of MCL-1 in facilitating mitochondrial physiology, especially promoting 
OXPHOS, may be beneficial to promote cancer stem cell proliferation. Therefore, it is 
possible that augmenting the function of matrix MCL-1 could be an effective strategy to 
induce differentiation and deplete the cancer stem cell pool. Further studies are required 
to separate the two functions of MCL-1 and find out their relative contribution to cancer 
initiation and maintenance.  
 
 
Potential Concerns of Targeting MCL-1 in Cancer Therapies 
 
 MCL-1 is essential for the survival and development of various cell types and 
inhibition of MCL-1 results in massive cell death and tissue dysfunctions, as discussed 
earlier [16-21, 26]. A previous study on S63854 provides preclinical evidence that MCL-
1 is a promising therapeutic target and its inhibition is efficacious and tolerable, which 
may be explained by the MCL-1 dosage effect. Cancer cells are always displaying 
increased copies of MCL-1 to avoid undergoing apoptosis, therefore, they are more 
dependent on MCL-1 and more vulnerable than normal cells. However, for many cells 
and tissues that are highly dependent on MCL-1 for survival and homeostasis, potential 
adverse side effects will need to be monitored when targeting MCL-1.  
 
 Severe thrombocytopenia from ABT-263, navitoclax, is a good example that its 
target BCL-XL is an essential pro-survival molecule for megakaryocyte survival to 
produce platelets [151, 165, 166]. Importantly, our data demonstrate that the anti-
apoptotic character of MCL-1 is required to keep embryonic stem cells surviving.  Both 
anti-apoptotic and Matrix forms are essential for efficient cellular differentiation. Other 
studies also suggest that MCL-1 is indispensable for cardiac homeostasis, hematopoiesis, 
and other functions [17-21, 26]. Therefore, the potential adverse side effects associated 
with pharmacological MCL-1 inhibition should be monitored, such as tissue 
differentiation and regeneration defects, cardiotoxicity, as well as pancytopenia.  
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CHAPTER 5.    FUTURE DIRECTIONS 
 
 
Contributions of Both MCL-1 Species for ESCs Survival and Differentiation 
 
Previous work from our laboratory has revealed that two forms of MCL-1 possess 
different functions due to their distinct localization [38]. Outer mitochondrial membrane 
localized MCL-1 performs the classical anti-apoptotic function by antagonizing BAX and 
BAK. However, N-terminal proteinase processed matrix localized MCL-1 does not 
possess anti-apoptotic activity, but plays a role in promoting mitochondrial physiology, 
including maintaining mitochondrial ultrastructure, facilitating mitochondrial fusion and 
fission, supporting the assembly of ATP synthase oligomers and oxidative 
phosphorylation [38]. Our data show that N-terminal truncated 30 kD mutant ESCs, 
although maintaining MCL-1’s anti-apoptotic function to help ESCs to survive, fail to 
differentiate to broad germ lineages, indicating that function of MCL-1 beyond 
antagonizing cell death is required for efficient cellular differentiation. Additionally, 
rescue experiments by putting back different isoforms of MCL-1 showed that only WT 
MCL-1 is capable of rescuing the differentiation defect of teratoma formation. Neither 
anti-apoptotic only CS10, 11 MCL-1 nor mitochondria Matrix species can completely 
rescue the differentiation defect, further suggesting both forms of MCL-1 are essential for 
ESCs survival and differentiation.  
 
 
Differentiation Rescue Experiments by Enforced Expression of MCL-1 Species 
 
 Our data demonstrate that only WT MCL-1 is capable of rescuing the 
differentiation defect but neither OMM mutant anti-apoptotic CS10, 11 MCL-1 nor 
mitochondria matrix species completely rescues the defect. Our future experiment will be 
to enforce the expression of both forms of MCL-1 in Mcl-1-deficient ESCs to see if we 
can get the complete rescue of differentiation.  We could first transduce Mcl-1flox/flox 
CREERT2 ESCs overexpressing MSCV-IRES-GFP 30 kD or CS10, 11 MCL-1 with MSCV-
I-mCherry Matrix MCL-1 and examine whether the 30 kD plus Matrix or CS10, 11 plus 
Matrix MCL-1 ESCs are able to differentiate into multiple germ layers. To avoid multiple 
rounds of transduction and flow sort, we could generate one construct with both 30 kD 
and Matrix or CS10, 11 and Matrix connected by a 2A peptide [167].  
 
 Another strategy will be to first overexpress different MCL-1 mutants, 30 kD, 
CS10, 11 or Matrix MCL-1, to the F12 ESCs and then performing the CRISPR-Cas9 
targeting on the endogenous MCL-1. If both forms of MCL-1 are required for ESCs 
differentiation, we expect to see that endogenous 30 kD mutant ESCs generated from 
CRISPR-Cas9 overexpressing Vector, 30 kD or CS10, 11 MCL-1 will fail to differentiate 
to any committed lineages. However, ESCs expressing the endogenous 30 kD mutant 
transduced with either WT or Matrix MCL-1 should be able to undergo efficient 
differentiation. By examining the design of our previous guide RNAs, crRNA-R1 could 
be used to target the endogenous MCL-1 but sparing the exogenous MCL-1 mutants 
because it targets the 5’-UTR of Mcl-1 genomic DNA.  
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Determine Mechanistically How Both Forms of MCL-1 Regulate ESCs 
Differentiation 
 
 
Determine Physiological Mitochondrial Status of Mutant ESCs 
 
 Our work indicates both forms of MCL-1 are indispensable for efficient 
differentiation of ESCs. However, future studies are needed to understand the 
mechanisms by which OMM and Matrix MCL-1 collaborate to regulate cellular 
differentiation. It is conceivable that OMM anti-apoptotic MCL-1 supports ESCs survival 
by antagonizing BAX and BAK.  This was suggested by our previous evidences that no 
clone with complete Mcl-1 deletion survived after CRISPR-Cas9 targeting and Mcl-1-
deleted ESCs failed to expand in culture. Matrix MCL-1, however, may promote the 
metabolic switch from aerobic glycolysis to OXPHOS by facilitating mitochondrial 
physiology for ESCs to undergo differentiation.  
 
 Therefore, it is important to determine the physiological mitochondrial status of 
WT ESCs comparing 30 kD mutant ESCs and Mcl-1flox/flox CREERT2 ESCs in the presence 
or absence of tamoxifen. We could measure ATP production, oxygen consumption, 
mitochondrial fusion and fission, supercomplexes of electron transport chain (ETC), 
mtDNA and mitochondrial membrane potential. Previous work from our laboratory 
suggests Matrix MCL-1 plays a role in maintaining mitochondrial ultrastructure, 
facilitating mitochondrial fusion and fission, supporting the assembly of ATP synthase 
oligomers and oxidative phosphorylation. Therefore, we expect to see that 30 kD mutant 
ESCs or Mcl-1-deleted Mcl-1flox/flox CREERT2 ESCs, lacking Matrix MCL-1, have 
defective mitochondrial respiration, decreased production of ATP and mtDNA, abnormal 
mitochondrial ultrastructure as well as the disrupted electron transport chain 
supercomplexes. Further experiment will be required to re-intrduce different mutants of 
MCL-1 to see whether OMM anti-apoptotic MCL-1 or Matrix MCL-1 rescues the 
mitochondrial physiology defects. We expect to see that WT MCL-1 or Matrix MCL-1 
corrects the mitochondrial physiology defects of 30 kD mutant ESCs. 
 
 
Determine Mechanistically How MCL-1 Regulates ESCs Differentiation 
 
 Our preliminary data suggested that when being induced by differentiation, full-
length MCL-1 protein expression was first increased peaking around 24 hours and then 
decreasing around 30% at EB day 10 compared with ESCs at the starting point  
(Figure 5-1A and B). The expression pattern of mRNA levels of Mcl-1 was consistent 
with its protein expression, showing that Mcl-1 transcription was dramatically induced 
for the first 24 hours of the differentiation process before the level dropped at the latter 
time point (Figure 5-1C and D). Dab-2 mRNA level was performed as a positive control, 
showing that the extraembryonic endoderm marker was induced along the differentiation 
process (Figure 5-1E and F). These data suggest that MCL-1 may be an early response 
gene under the regulation of either cytokines or signaling pathways during differentiation. 
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Figure 5-1. MCL-1 expression is first induced and then decreased during 
differentiation process 
(A) Immunoblotting of F12 WT ESCs and embryoid bodies at different time point along 
the differentiation for MCL-1, PARP, Caspase 3 and Actin. (B) Relative expression of 
MCL-1 protein levels along the differentiation time course. (C) Real-time PCR of 
induction fold change of control for Mcl-1 mRNA along the differentiation time course. 
(D) The curve of relative expression of Mcl-1 mRNA levels during the differentiation 
time course. (E) Real-time PCR of induction fold change of control for Dab2 mRNA 
along the differentiation time course. (F) The curve of relative expression of Dab2 
mRNA levels during the differentiation time course. The assay was done in triplicate for 
each sample. Error bars represent the standard error of the mean.    
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We further performed microarray analysis on Mcl-1flox/flox CREERT2 ESCs in the 
presence or absence of tamoxifen. Principal components analysis (PCA) is a statistical 
technique for demonstrating the key variables of multidimensional data set.  It can be 
used to simplify the analysis by visualization [168]. Our PCA and corrected PCA data 
suggested that Mcl-1flox/flox CREERT2 ESCs control and Mcl-1-deleted ESCs were very 
different across gene expression data sets (Figure 5-2A and B). Additionally, our gene 
set enrichment analysis (GSEA) revealed many potential pathways involved. 
Understandably, pathways being correlated with tumorigenesis, progression and invasion 
have been identified because anti-apoptotic MCL-1 has been suggested to be involved in 
cancer initiation, progression and relapse as we discussed earlier. Other than the possible 
anti-apoptotic pathways, there are two top targets identified that may be relevant, SUZ12 
and the epithelial to mesenchymal pathway (Figure 5-2C and D).   
 
 SUZ12 (suppressor of zeste 12), a Polycomb group (PcG) protein, together with 
EZH2 (enhancer of zeste homolog 2) and EED (embryonic ectoderm development) form 
the Polycomb repressive complex, PRC2 [169, 170]. SUZ12 is essential for PRC2 
activity to repress transcription through methylation of lysine (K) 27 of histone (H3) 
(H3K27 methylation).  Inactivation of SUZ12 results in early lethality of mouse embryos 
[171, 172]. It has been further shown that Suz12-/- ESCs failed to undergo proper 
differentiation upon induction suggesting that SUZ12 is required for the repression of 
genes essential for ESCs self-renewal, like Nanog and Oct4 [171]. Mcl-1-null ESCs 
downregulated SUZ12, which is consistent with the differentiation defect phenotype 
(Figure 5-2C).  Future studies need to focus on how MCL-1 and SUZ12 are related to 
facilitate ESCs differentiation. It is possible that SUZ12 is downstream of MCL-1, 
thereby regulating the global methylation of H3K27.  To test the hypothesis, SUZ12 
overexpression experiment could be performed in Mcl-1-deleted or 30 kD mutant ESCs 
to examine whether restoration of SUZ12 is capable of rescuing the differentiation defect. 
If SUZ12 is the downstream effector of MCL-1, chromatin immunoprecipitation 
sequencing (ChIP-Seq) and RNA sequencing (RNA-seq) could be initiated to understand 
potential genes regulated by epigenetic control via the MCL-1-SUZ12 pathway.  
 
Another pathway identified by GSEA was the upregulated epithelial to 
mesenchymal transition (EMT) in Mcl-1-deleted ESCs (Figure 5-2D). Consistent with 
our previous discussion, one study suggested that MCL-1 interacts with STAT3 at the 
window of implantation to promote the mesenchymal to epithelial transition (MET), 
essential for successful implantation [142, 143]. Therefore, it will be also important to 
test how MCL-1 interacts with STAT3 to facilitate MET for ESCs differentiation and 
embryo implantation. First, we could evaluate the expression level, subcellular 
localization and phosphorylation status of STAT3 in the presence or absence of MCL-1. 
If there is a difference, we could test whether restoration of STAT3 levels rescues the 
differentiation defect. Furthermore, there are many STAT3 mutants (constitutively active, 
dominant negative, or catalytic-dead mutant STAT3) that we could use to test how MCL-
1 and STAT3 interact with each other.  
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Figure 5-2. Potential changes of signaling pathways are identified in Mcl-1-
deleted ESCs  
(A) Principal components analysis and (B) corrected PCA data comparing Mcl-1flox/flox 
CREERT2 ESCs control and Mcl-1-deleted ESCs. (C) Top 1st and (D) top 4th hits of 
possible downregulated and upregulated signaling pathways from GSEA by comparing 
Mcl-1-deleted ESCs versus Mcl-1flox/flox CREERT2 ESCs control. Mcl-1flox/flox CREERT2 
ESCs treated with 48 hours tamoxifen were statistically tested by unequal variance t test 
to the DMSO control (3 replicates). P values for both downregulated SUZ12 and 
upregulated EMT pathways are 0.000.  
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Determine the Phenotypes of CS10, 11 and 30 kD MCL-1 KI Mice 
 
 Our work showed that CS10, 11 and 30 kD MCL-1 KI heterozygous were 
successfully derived. Because of potential off-target effects from CRISPR-Cas9 
targeting, our F1 heterozygous mice were backcrossed to WT C57BL/6 mice [173]. After 
backcrossing, they will be crossbred and the Mendelian ratio will be calculated. Future 
experiments will set out to try to figure out the phenotypes of CS10, 11 and 30 kD MCL-1 
KI Mice. To determine whether CS10, 11 and 30 kD MCL-1 KI ESCs have defects in 
differentiation, ESCs from KI homozygous mice will be derived and differentiation 
assays will be repeated. It will be also interesting to check whether there are any defects 
in hematopoiesis, cardiac homeostasis, and malignant transformation, where both forms 
of MCL-1 seem to play important roles. 
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